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„Der Mensch wird vom Gedanken geschaffen. 
Ein Mensch wird das, woran er denkt. 
Denke, du bist stark; Du wirst stark werden. 
Denke, du bist schwach; Du wirst schwach werden. 
Denke, du bist töricht; Du wirst ein Dummkopf werden. 
Denke du bist Gott; Du wirst Gott.“ 
 
Swami Sivananda 
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1. Summary / Zusammenfassung 
 
1.1. Summary 
Translation control is an important mechanism to regulate polypeptide production during 
physiological processes. Extrinsic and intrinsic factors control the availability of the 
translation machinery including eukaryotic initiation factors (eIFs), thus influencing the 
different steps in messenger RNA (mRNA) translation. Besides cap-dependent initiation 
mechanisms of translation, several mRNAs harbor an internal ribosome entry site (IRES) 
within the 5´-untranslated region (UTR) for alternative translation, which is suggested to 
have severe implications in tumorigenesis.  
Laminin B1 (LamB1) represents an extracellular matrix (ECM) protein involved in ECM-
cell interactions which affects cell migration, proliferation and differentiation. Recent 
studies correlated enhanced LamB1 receptor expression with cancer cell invasiveness. 
Furthermore, LamB1 was detected to be translational upregulated during hepatocellular 
epithelial to mesenchymal transition (EMT). In addition, it has been suggested that the 
LamB1 5´-UTR contains an IRES element that is responsive to changes during 
malignant progression of hepatocytes.  
In this study, we show that the LamB1 5´-UTR is able to direct translation of a bicistronic 
reporter construct in murine neoplastic hepatocytes. Furthermore, both mitogen-activated 
protein kinase and phosphatidylinositol-3-kinase signaling might be crucial for cap- and 
cap-independent LamB1 translation during EMT of hepatocytes. Notably, expression of 
bicistronic reporter constructs containing deletions of the LamB1 5´-UTR revealed that 
the region from 155 to 335 cannot retain a full IRES activity. Therefore, we suppose that 
the nucleotide sequence 1 to 155 of the LamB1 5´-UTR might be indispensable for 
LamB1 IRES activity. Recent data suggest that 3´-UTRs of mRNAs are able to modulate 
cap-dependent translation via interaction of the poly(A)-binding protein with eIF4G. 
Therefore, we investigated the regulatory role of LamB1 3´-UTR on translation in a 
monocistronic reporter assay. Notably, we found that the effect of the LamB1 3´-UTR 
might depend on the sequence located upstream of the reporter gene. In particular, an 
inhibitory role of the LamB1 3´-UTR on the LamB1 5´-UTR-dependent translation was 
detected in hepatocytes that have undergone EMT. On the contrary, the 3´-UTR of the 
interleukin like EMT inducer (ILEI) was able to promote translation in mammary 
carcinoma cells. Altogether, these data show novel insights into the cis-acting regulatory 
motif of the LamB1 IRES and the impact of the trailer in the translation control of LamB1.  
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1.2. Zusammenfassung 
Die Kontrolle der Translation ist eine wichtige regulatorische Ebene der Genexpression 
während vieler physiologischer Prozesse. Extrinsische und intrinsische Faktoren, wie 
zum Beispiel eukaryotische Initiationsfaktoren (eIF), kontrollieren die Aktivität des 
Translationsapparates und damit die Translation der messenger RNA (mRNA). Einige 
mRNAs besitzen eine „ Internal Ribosome Entry Site“ (IRES) in ihrer 5´untranslatierten 
Region (5´-UTR), die eine alternative Initiation der Translation zu cap-abhängigen 
Mechanismen ermöglicht und eine wichtige Rolle in der Tumorigenese einnimmt.  
Laminin B1 (LamB1) ist ein Protein der extrazellulären Matrix (ECM), welches die 
Migration, Proliferation und Differenzierung der Zellen beeinflusst. Kürzlich konnte ein 
Zusammenhang zwischen der verstärkten Expression des LamB1 Rezeptors und der 
Tumorinvasion nachgewiesen werden. Weiters wurde festgestellt, dass LamB1 während 
der epithelialen zu mesenchymalen Transition (EMT) von Hepatozyten translationell 
aktiviert wird. Nach letzten Untersuchungen ist es sehr wahrscheinlich, dass ein IRES 
Element innerhalb der 5´-UTR von LamB1 für dessen Translation während der 
Tumorprogression verantwortlich ist.  
Die vorliegende Untersuchung zeigt, dass der 5´-UTR von LamB1 die Translation eines 
bicistronischen Reporterkonstrukts in neoplastischen Hepatozyten steuert. Zudem sind 
zwei Signalwege, der „Mitogen-Activated-Potein-Kinase“ –Weg und der 
„Phosphoinositid-3-Kinase“ -Weg wesentlich an der cap-abhängigen und cap-
unabhängigen Translation von LamB1 während der Hepatozyten EMT beteiligt. 
Interessanterweise zeigt der Sequenzbereich 155 bis 335 des LamB1 5´-UTR im 
bicistronischen Reporterassay funktionell nicht die volle IRES Aktivität. Damit scheint die 
Sequenz 1 bis 155 für die volle LamB1 IRES Aktivität unentbehrlich zu sein. Neue 
Ergebnisse deuten darauf hin, dass die 3´-UTRs die cap-abhängige Translation durch 
eine Interaktion des Poly(A)-bindenden Proteins mit dem eIF4G modulieren können. 
Daher haben wir die regulatorische Funktion der LamB1 3´-UTR in der Translation 
mittels monocistronischen Reporterassays untersucht. Wir konnten zeigen, dass dessen 
Funktion möglicherweise von der, dem Reportergen vorgelagerten Sequenz abhängig 
ist. Der LamB1 3´-UTR wirkte hemmend auf die LamB1 5´-UTR gesteuerte Translation in 
Hepatozyten nach EMT. Im Gegensatz dazu konnte der 3´-UTR des „Interleukin Like 
EMT Inducer“ (ILEI) die Translation in Brustkrebszellen verstärken. Diese Daten geben 
einen neuen Einblick in die „cis-agierenden“ regulatorischen Elemente des LamB1 IRES 
und der Auswirkung des 3´-UTR auf die Kontrolle der Translation von LamB1. 
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2. Introduction 
 
2.1. Tumorigenesis 
 
Tumorigenesis is considered as a complex sequence of events usually evolving over 
many years [1-3]. The generally accepted model describes a multistage process divided 
into three phases: tumor initiation, tumor promotion and tumor progression [3]. Genetic 
alterations in the genome, caused by e.g. chemical carcinogens, designate the initial 
phase of tumorigenesis. Particularly, mutations in genes involved in the regulation of cell 
growth and differentiation, which are known as proto-oncogenes and tumor suppressor 
genes, display a hallmark in the onset of cancer [1, 3]. Activated oncogenes support 
tumorigenesis by promoting cell growth and cell division. In contrast, mutational 
inactivation of tumor suppressor genes enable a cell to evade apoptosis and overcome 
senescence [3-4]. Together, these irreversible alterations of the genome drive the 
progressive transformation of normal cells into malignant tumor cells [1-3]. Increased cell 
growth and clonal expansion of neoplastic cells allow the formation of macroscopic 
tumors. Inflammation processes and disintegrated cytokine signaling in the surrounding 
tissue promote tumor malignancy [3]. Finally, additional spontaneous genomic mutations 
accompanied by alterations in the tumor microenvironment facilitate tumor invasion and 
progression [5-6]. During this third stage, the highly malignant cancer cells acquire 
capabilities allowing them to invade the surrounding tissue and intravasate into the 
bloodstream in order to form distal metastasis. Epithelial to mesenchymal transition 
(EMT) is a central event in this context, contributing to the tumor cell heterogeneity and 
metastatic progression [6].  
During the last decades, cancer research has generated a rich body of knowledge 
concerning tumorigenesis and its underlying mechanisms. Multiple mechanisms that 
govern the transformation of normal human cells into malignant cancer cells have been 
revealed [3, 7]. In general, six or even seven essential alterations in cell physiology of 
normal cells collectively promote malignant growth: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, tissue invasion and metastasis as 
well as the inflammatory tissue context (Figure 1) [3, 7].  
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Figure 1.  Mechanisms of tumorigenesis [3, 7]. 
 
 
Each of the listed alteration reflects the successful evasion of complex control and 
anticancer defence mechanisms present in normal cells. Notable, the particular 
sequence in which capabilities are acquired can vary among tumors types and 
individuals [3].  
Normal cells require mitogenic growth signals (GS), such as diffusible growth factors or 
extracellular matrix (ECM) components in order to initiate proliferation via specific 
receptors [8]. In tumor development, some oncogenes mimic normal growth signaling, 
thus liberating cells from the dependence on stimulation by their microenvironment. 
Consequently, mechanisms that mediate tissue homeostasis are frequently disrupted [3, 
7]. There are various molecular strategies in order to achieve GS autonomy. Some 
cancer cells acquire the ability to stimulate their own proliferation by creating an 
autocrine positive feedback loop. For example, platelet-derived growth factor (PDGF) 
and the tumor necrosis factor (TNF)α are frequently regulated by autocrine stimulation in 
tumors [3, 7]. Other cancer cells overexpress growth factor (GF) receptors, thus 
amplifying growth-stimulatory signals. The expression of truncated receptor versions 
lacking the cytoplasmic domain displays another mechanism to achieve a constitutive 
active ligand-independent signaling [3, 7]. Furthermore aberrant regulation of 
downstream signaling pathways is frequently observed. In normal cells, signals from 
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ligand-activated GF receptors and integrins are transduced via cytoplasmic downstream 
effectors into the nucleus, where gene expression is regulated. The SOS-Ras-Raf-MAPK 
cascade plays a central role in this context [3]. This signal transduction cascade is linked 
to several other pathways, thus influencing multiple cellular processes. Notably, Ras 
proteins are structurally altered in about 25% of human tumors, leading to a constitutive 
activation of mitogenic signaling [3, 9]. In addition to these cell autonomous mechanisms, 
malignant cell proliferation requires also tumor-stroma mediated paracrine growth 
stimulation. Tumor cells frequently acquire the abilitiy to secrete GFs in the surrounding 
tumor microenvironment [3, 10].  
Soluble inhibitors are also involved in the maintenance of tissues homeostasis. These 
anti-growth signals transfer cells from active proliferation into a quiescent state (G0) or 
induce the irreversible transition into a postmitotic state, which is usually accompanied 
with cell modulation of differentiation [3]. In general, anti-proliferative signals are 
transduced by the retinoblastoma protein (pRb) which is hypophosphorylated and 
subsequently blocks proliferation by altering the function of E2F, a transcription factor 
that controls the expression of genes essential for the progression from G1 into S phase 
[11]. pRb signaling is disrupted in many tumors, enabling the cells to proliferate despite 
of anti-growth signals. A prominent soluble signaling molecule in this context is 
transforming growth factor ß (TGF-ß). Among its various functions, TGF-ß prevents Rb 
inactivating phosphorylation by induction of cell cycle inhibitors such as p15INK4B. In this 
line, it blocks cell cycle progression at the G1 checkpoint [3, 12]. Interestingly, some 
tumors acquire the ability to overcome the blocked cell cycle progression. To evade the 
TGF-ß mediated homeostasis, tumor cells frequently lose their TGF-ß responsiveness by 
mutational inactivation or downregulation of TGF-ß receptor expression [3, 13]. 
Additionally, functional pRb and other important regulators can be lost by gene mutation 
[3]. 
Programmed cell death represents another mechanism in order to maintain tissue 
homeostasis [3]. The apoptotic machinery contains sensors and effectors. Specific 
survival factors such as Insulin-like growth factor (IGF)-1/-2 and death factors such as 
FAS ligand bind to their corresponding receptors and determine cell fate. Importantly, cell 
survival can be ensured by the maintenance of tissue architecture which is controlled by 
cell-matrix and cell-cell adherence-based survival signals [3, 14]. Additionally, 
intracellular sensors such as p53 or members of the Bcl-2 family monitor changes within 
the cell and activate the death pathway in response to genomic abnormalities, signaling 
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imbalance, survival factor insufficiency or hypoxia [3, 15-16]. Once the death pathway is 
activated, intracellular proteases termed caspases execute the death program through 
selective and well-ordered destruction of subcellular structures, organelles and the 
genome [3]. Tumor cells developed strategies to impair proapoptotic pathways and 
acquire resistance towards apoptosis. One prominent example is the loss of the tumor 
suppressor p53, which happens in approximately 50 % of human cancers [3]. 
Furthermore, the activation of JAK/STAT, PI3K/AKT and RAS/ERK pathways is 
frequently enhanced in many tumors including hepatocellular carcinoma (HCC) [17]. In 
fact, alterations of the apoptotic machinery can dramatically affect the dynamics of tumor 
progression.   
An indispensable event during progressive transformation of normal cells towards 
malignancy is the acquisition of a limitless replicative potential [3, 7]. Normal cells show a 
finite replicative potential that limits their cell doublings. Once a cell has progressed 
through a certain number of doublings, it stops growing, a process which is called 
senescence [3, 18]. Senescence can be circumvented by disabling the pRb and p53 
tumor suppressor proteins allowing the cell to continue replication until it enters the state 
of crisis [3]. Crisis is characterized by massive cell death as well as the occasional 
occurrence of an altered (1 in 107) cell that acquires the ability of limitless replication and 
immortalization [3]. At this point, the cell has completely disrupted the primary intrinsic 
cell-autonomous program that limits cell proliferation. The immortalized phenotype of the 
cell is essential for the development of a malignant growth state [3]. Immortalized cells 
require an enhanced maintenance of telomeres, which is supported  by the upregulated 
expression of telomerase enzyme in malignant cells [3, 19].  
Survival of tumor cells depends as well on adequate supply with oxygen and nutrients 
[3]. In order to progress in size, emerging neoplasias must develop angiogenic abilities. 
Multiple observations indicate that neovascularization is a prequisite to the rapid clonal 
expansion associated with the formation of macroscopic tumors [3, 20]. Angiogenesis is 
regulated and kept in balance by positive and negative signals. A dimension of regulation 
comprises the proteases which control the bioavailability of angiogenic activators and 
inhibitors [3]. Tumor cells are able to induce an angiogenic switch by altering the balance 
of angiogenic inducers and inhibitors [3]. 
It is well recognized that all cancers acquire the same capabilities: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory signals, apoptosis, limitless replicative 
potential and sustained angiogenesis [3]. These capabilities are indispensable for a 
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tumor cell to invade the surrounding tissue, to spread throughout the body and to 
colonize at distant place as metastasis. Tissue invasion and metastasis are essential 
steps during tumor progression [6]. E-cadherin, an important adherence protein links 
adjacent cells and therefore serves as a suppressor of invasion and metastasis. The 
generation of cell contacts by E-cadherin induces antigrowth signals which are 
transduced via cytoplasmic bound ß-catenin affecting many intracellular signaling 
pathways [3]. The functional loss of E-cadherin represents a key step in the acquisition of 
the capability to invade and to metastasize. During the invasion process, malignant cells 
are supported by matrix-degrading proteases produced by stromal and inflammatory 
cells. However, successful cancer cells additionally alter their binding specifities for 
cadherins, cellular adhesion molecules (CAMs), and integrins in order to acquire invasive 
and metastatic abilities. Notably, the molecular mechanisms and responsible regulators 
that govern cell invasion are tissue and context dependent [3, 6]. 
Mutations and changes within the genome of cancer cells are the cause of an increase in 
mutability [21]. Mutation of specific genes is not sufficient enough to cause cancer. 
Repair enzymes and DNA protecting factors maintain the genomic integrity and ensure 
that DNA sequence information remain pristine. Therefore, malfunction of these genomic 
“caretakers” has been proposed as an explanation for the increased mutability in 
malignant cells [22]. Accordingly, genomic instabilities appear to enable evolving 
populations of premalignant cells to reach these six or even seven capabilities. Moreover 
cancer development should be considered as a rather complex process that is also 
controlled and affected by the tumor microenvironment [3, 5].  
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2.2. Hepatocellular carcinoma (HCC) 
 
Hepatocellular carcinoma (HCC) is the third most lethal cancer and represents the fifth 
most common cancer worldwide [23-25]. The prevalence of HCC is very high in 
developing countries, like from Asia and Africa but current data foresee a steady 
increase of HCC incidences in the Western countries [26]. The wide geographical 
distribution of HCC can be explained by the heterogeneity of risk factors [25, 27]. 
Generally, any agent that leads to chronic liver injury is considered as a risk factor for 
HCC. Hepatitis C infections and excessive alcohol abuse are the leading causes for HCC 
in Western countries, whereas aflatoxin B1 ingestion and hepatitis B infections are 
mainly responsible for the high HCC incidence in Asia and Africa [24, 27].  
The development of HCC takes about several decades. In the majority of cases no 
obvious symptoms are present at early stages, hindering an early diagnosis. Generally, 
chronic hepatitis, fibrosis and/or cirrhosis, caused by the mentioned risk factors, are 
accompanied by phenotypic alterations of hepatocytes, an event considered to be pivotal 
for the onset of HCC (Figure 2) [23-25]. Inflammatory processes and the incipient 
destruction of liver structure challenge liver regeneration systems [24].  
The molecular events which promote the development and progression of HCC are still 
not completely understood. Consequently, current therapies are yet not as successful as 
for other cancer types leading to poor survival of HCC patients after diagnosis [24, 27]. 
Untreated intermediate or advanced stage HCCs are characterized by a median survival 
of six to sixteen months [27]. Furthermore, the incidence of metastases is very high and 
predominantly occur in bones, lung, peritoneum, pancreas and brain [28-30]. 
Actually, the therapy options mostly depend on macroscopic parameters such as tumor 
size and number [23]. Surgical resection of the tumor presents an option for patients 
diagnosed at early tumor stages, showing solid tumor nodules with well-preserved liver 
function. After successful surgery, the five years survival rate lies between 60 – 70 %, 
but unfortunately in up to 70 % of the cases, HCC recurrence is observed [23]. Liver 
transplantation, a potent therapeutic strategy, achieves the same outcome concerning 
the five years survival rate, and shows a lower recurrence rate compared to surgical 
therapy [23]. Another treatment option is the percutaneous ablation, where tumor tissue 
is ablated by ethanol injection or radiofrequency. The success of this therapy mostly 
depends on the tumor size, but under optimal conditions it leads to a recovery in 80% of 
cases [23]. Additionally, the trans-arterial percutaneous chemoembolization (TACE), 
‘Translational regulation of Laminin B1 and ILEI during cancer progression’                  Hau Mara                   
 
 14
aims to reduce symptoms as a palliative therapy during late tumor stages [23, 31]. 
Therefore, a chemotherapeutic drug is injected into hepatic arteries, leading to the 
obstruction of the tumor feeding vessels [27, 30].  
Sorafenib, is a new promising therapeutic drug for the treatment of advanced HCC 
stages [32]. The agent blocks important molecular mechanisms by targeting Raf 
signaling, PDGF-receptor and vascular endothelial growth factor  receptor (VEGF-R). 
PDGFR-α is involved in tumor angiogenesis and maintenance of the tumor 
microenvironment, and has been found to be implicated in the development and 
metastasis of HCC [32-34].  
Due to the predicted increase of HCC for the next several decades, the identification of a 
potential prognostic factor is of particular importance. Extensive tumor  
hypervascularisation as well as the invasiveness of HCC have recently been linked to 
high VEGF levels [35-36]. Therefore VEGF is discussed as a prognostic marker [25]. 
 
 
Figure 2.  Pathogenesis of hepatocellular carcinoma (HCC) [24]. 
 
 
Generally, hepatocytes are highly differentiated epithelial cells which are of paramount 
relevance for glucose, amino acid and lipid metabolism. These cells are mitotically 
inactive under physiological conditions. However, in response to liver damage, 
hepatocytes show an extraordinary proliferative capacity for regeneration [37-38]. 
Interestingly, aberrant proliferation and dedifferentiation of hepatocytes are observed 
during the pathogenesis of HCC. While our knowledge of genetic and epigenetic 
alterations leading to HCC is rapidly growing, the molecular pathogenesis of HCC is still 
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poorly understood. Nevertheless, various studies on human HCCs revealed some 
molecular events that may play crucial roles in human hepatocarcinogenesis [39-41]. 
Most frequently occurring molecular alterations in HCC include (i) the loss of tumor 
suppressors such as p53, pRB, p14ARF, p16INK4A and cyclins/cdks, (ii) the loss of the cell-
cell adhesion protein E-cadherin, (iii) the constitutive activation of signaling pathways – 
e.g. Erk/MAPK and PI3K pathway, (iv) the nuclear accumulation of Wnt/ß-catenin, and 
(v) the aberrant regulation and secretion of cytokines such as TGF-ß [38-41].  
In several tumor models including human HCC models, the cooperation of oncogenic 
Ras and TGF-ß induces progression to undifferentiated invasive tumors which are 
characterized by migratory and fibroblastoid cell phenotypes [38, 42-43]. This 
phenotypical conversion of cells, termed epithelial to mesenchymal transition (EMT), is 
increasingly recognized as a central process during cancer progression and metastasis 
[43-44].  
 
2.3. Epithelial to mesenchymal transition (EMT) in embryonic development 
 
EMT is a highly conserved and fundamental process that plays key roles in many steps 
of normal morphogenesis [45-46]. Differentiated epithelial cells switch into motile 
mesenchymal cells allowing the cells to migrate and generate new tissues during 
embryogenesis (Figure 3) [47]. EMT is described as a morphological conversion of 
epithelial monolayered cells into single dispersed fibroblastoids. In particular, epithelial 
polarized cells, which are merely able to move laterally in the epithelial layer by retaining 
contact to the basal lamina, undergo a phenotypical conversion characterized by the gain 
of mesenchymal, fibroblastoid-like properties such as increased motility combined with 
the loss of intercellular adhesion [46, 48-49].  
 
 
Figure 3. The epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) 
[47]. 
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This phenomenon has been first described as an indispensable process during distinct 
steps of embryogenesis, including gastrulation and the migration of cells from the 
primitive neural crest throughout the embryo [6, 48].   
During the last years, investigations have shown that EMT is programmed and regulated 
by a variety of selected transcription factors (TF) and cytokines which have the potential 
to activate EMT at specific sites within the embryo [6, 50]. The persistent expression of 
these TFs in EMT transformend cells indicates that a downregulation of the TFs may 
lead to the loss of EMT-inducing effects reverting the EMT. This morphogenetic 
reversion is referred to  as mesenchymal to epithelial transition (MET) [46, 48, 51]. 
Observations of EMT events that are restricted to specific locations within the embryo 
suggested that EMT is a consequence of specific contextual signals received from the 
local microenvironment [6]. Interestingly, similar epithelial changes can be observed 
during different physiological processes such as wound healing and pathological 
processes such as chronic inflammation which is a preliminary stage to fibrotic diseases 
[52]. During the last years, investigations have revealed an important role of EMT in 
tumorigenesis [48]. The fact that many TFs that orchestrate EMT during embryogenesis 
are also found to be expressed in various human cancers, additionally supports its 
relevance to cancer pathogenesis [6]. Today the EMT process is considered as a crucial 
step in tumor progression allowing cancer cells to disseminate from the primary tumor 
and to cause local invasion and metastasis at distant sites [6, 46, 48].  
 
2.4. Epithelial to mesenchymal transition (EMT) in tumor progression 
 
EMT describes a developmental event that is increasingly recognized to play an 
essential role during cancer progression and metastasis [6, 38, 48]. The generally 
accepted model of carcinogenesis and metastasis describes a step by step development 
of the malignant increase (Figure 4) [48]. Normal epithelial cells, lined by a basement 
membrane display an apical - basal polarization and are functionally differentiated. 
Epithelial cells are organized via cell-cell contacts such as tight and adherence junctions 
in order to form intact epithelial layers. Initial malignant transformations induced by 
epigenetic and molecular alterations cause a carcinoma in situ, which is characterized by 
an intact basement membrane [3, 48]. Subsequently, a cascade of alterations leads to 
the formation of cells which escaped physiological cell control [3]. For example, by 
evading apoptosis and growth control, cells establish and maintain highly malignant 
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properties. Further, the malignant cells gain invasive properties, possibly enabled by 
undergoing the EMT process. Finally, less differentiated, invasive cells break through the 
basement membrane, intravasate into the lymphatic or blood system and subsequently 
spread throughout the organism [3, 48]. 
 
 
Figure 4.  Model of epithelial tumor development and metastasis [48]. 
 
In distant organs, small cell accumulations can form micrometastasis or the invaded cells 
establish a new carcinoma through the MET process [46, 53]. Therefore, EMT and its 
reverse mechanism, the MET, play a crucial role for tumor progression, by allowing 
malignant cells to escape from the solid tumor [47-48].  
As already mentioned above, the expression of EMT-inducing TFs in cancer cells in 
response to heterotypic signals by surrounding cells seems to play a crucial role during 
the process of carcinoma progression. These signals such as Wnts, Hedgehogs, 
members of the TGF-ß family as well as ligands of tyrosine kinase receptors are 
released by mesenchymal cells that form the tumor-associated stroma [6, 51]. It is 
assumed that these mesenchymal cells which are recruited either from the tissue stroma 
or the bone-marrow, become increasingly activated and reactive as tumor progression 
proceeds. The inflamed tumor-stroma may be the source of the heterotypic signals that 
evoke EMT. However, at distant sites of metastasis and in the absence of these 
stimulating signals, the cancer cells will decline expression of EMT-inducing TFs and 
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therefore undergo MET leading to an epithelial phenotype [6]. The subsequent fate of 
such disseminated tumor cells is still unclear. The cancer cell is confronted with a new 
microenvironment to which it is poorly adapted. It seems likely that out of thousands of 
micrometastasis only some few successfully grow into macroscopic metastasis [6, 48]. 
 
2.5. Signaling networks guiding EMT 
 
Within the EMT process, epithelial cells regulate epithelial-specific markers down, 
leading to the loss of typical epithelial features such as the ability to form adherens and 
tight junctions (Figure 5) [51]. Tight junctions are localized at the lateral side close to the 
apical surface enabling membrane fusions of epithelial cells. Maintained by occludins 
and claudins, the cytoplasmic components Zonula Occludens (ZO)-1,-2,-3 and p120 
attach to actin filaments, thereby contributing to the integrity of tight junctions [54]. 
Adherens junctions, located adjacent to the tight junctions in the basolateral surface 
compartments, are established by homotypic E-cadherin interactions. The cytoplasmic 
domains of E-cadherin bind tightly to ß-catenin that in turn anchors to the actin 
cytoskeleton. Structurally similar to the adherens junctions are the desmosomes which 
connect the cadherins to the intermediate filament cytoskeleton [51]. At the onset of 
EMT, tight junctions are dissocciated and E-cadherin gets lost which leads to a 
reorganization of the cytoskeleton [51, 55]. Subsequently, the mesenchymal phenotype 
becomes apparent by the expression of mesenchymal cytoskeletal proteins such as 
vimentin and the increased deposition of ECM proteins including fibronectin and 
collagens. These secreted ECM components stimulate integrin signaling and induce the 
formation of focal adhesion complexes (FAK), which facilitate cell migration [56]. Further, 
degradation of the basement membrane and remodeling of the actin cytoskeleton from 
cortical actin towards actin stress fibers takes place, which are a hallmark of migratory 
mesenchymal cells [29]. Besides non-transcriptional changes, all these processes 
additionally underly a plexus of changes in transcriptional regulation, leading to a 
repression of epithelial genes expression and an activation of mesenchymal gene 
expression [51].  
‘Translational regulation of Laminin B1 and ILEI during cancer progression’                  Hau Mara                   
 
 19
 
 
Figure 5.  The cycle of epithelial-cell plasticity [51]. 
 
 
E-cadherin, the epithelial membrane protein that provides cell-cell contacts, can be 
considered a tumor suppressor inhibiting invasion and metastasis [48]. Corroborating this 
theory, the re-expression of E-cadherin in carcinomas has been shown to be sufficient to 
reduce the aggressiveness of tumor cells in in vitro experiments [57]. The loss of 
functional E-cadherin is described as a consequence of mutations within the gene or as 
a result of epigenetic changes including promoter hypermethylation and transcriptional 
repression by prominent repressors such as Snail, Slug, ZEB1, ZEB2 and E12/E47 [48, 
58]. Additionally, the serin-threonine kinase AKT which is frequently activated in human 
epithelial cancer  was recently shown to regulate mRNA and protein levels of E-cadherin 
[59-60]. Another study revealed a collarboration of AKT-mediated activation of Rab5 
protein with E-cadherin sequestration [61].   
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Figure 6.  The major signaling pathways inducing epithelial-mesenchymal transition (EMT) [47]. 
 
 
However, loss of E-cadherin should not be considered as the sole pivotal event in EMT. 
In tumor progression as well as in development, several signal transduction pathways 
such as Src, Ras, Ets, integrin, Wnt/ß-catenin and Notch are involved in the onset and 
regulation of the EMT process [49]. Experimental data revealed a complex network of 
signaling pathways that cooperatively regulate epithelial plasticity (Figure 6) [47]. A major 
signaling pathway that is constitutively activated in tumors is the Ras/MAP-Kinase 
pathway. Growth factors such as hepatocyte growth factor (HGF), fibroblast growth 
factor (FGF) and PDGF bind their corresponding receptor tyrosine kinases (RTK) and 
activate Ras-Raf-MAPK, Posphatidylinositol-3´-kinase (PI3K) or Src-STAT signaling 
pathways [49]. Paracrine activation of TGF-ß signaling in cells with constitutive active 
Ras leads to the induction of EMT [62]. PI3K is a critical intracellular mediator of RTK 
signaling providing a cross-talk between growth factor signaling, integrin receptors and 
small GTPases of the Rho family in order to control cytoskeletal organization and to 
induce EMT [58]. Rho-GTPases and the expression of proteases such as matrix-
metalloproteinases (MMPs) and urokinase-type plasminogen activator (uPA) have a 
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strong impact on cell motility by remodelling the actin cytoskeleton and by degrading the 
ECM [58].  
Beside the established role of RTK signaling in EMT, observations in various cancers 
demonstrate a complex interplay of multiple signaling pathways including TGF-ß, PDGF, 
WNT and Notch, which cause activation of downstream Erk MAPK, ß-catenin and 
nuclear factor-κB signaling (NF-κB) [63].  
Numerous in vivo as well as in vitro models were established in order to study the EMT 
process. In vitro models are used to investigate individual signaling pathways by simple 
genetic manipulation, but the relevance of the data is still questionable [48-49, 62]. In this 
aspect, in vivo models reflect the human tumors more closely due to the presence of 
tumor microenvironment, which proved to have a strong regulatory influence on tumor 
progression and metastasis [64-67]. Despite the limitations of in vivo models, these 
experimental settings allow a more detailed study of the tumor-host interplay than in vitro 
models [68]. 
 
2.6. TGF-ß signaling in cancer progression 
 
Under physiological conditions, TGF-ß is involved in the regulation of cell proliferation, 
differentiation and apoptosis. Soluble TGF-ß binds to the TGF-ß receptor (TßR) II which 
results in heterodimerization and phosphorylation of the regulatory GS domain within 
TßRI [69]. Subsequently TßRI activates Smad2 and Smad3 through direct C-terminal 
phosphorylation and enables Smad2/Smad3 to bind Smad4, and translocate into the 
nucleus. In the nucleus numerous co-activators such as p300, CBP or SMIRF or co-
repressors such as p107 join the Smad complex in order to activate or repress target 
gene expression (Figure 7) [70-72]. Smad6 and Smad7 show inhibitory functions by 
preventing the activation of the receptor-regulated Smads [73]. Among all the various 
growth factors and differentiation factors, TGF-ß received much attention as a major 
inducer of EMT during embryogenesis, tumor progression and fibrosis. In fact, TGF-ß is 
a double-edged sword in tumorigenesis; on one hand  acting as a tumor suppressor and 
on the other hand as a tumor promoter [74]. During the early phase of epithelial 
tumorigenesis, suppressive TGF-ß signaling prevents epithelial cell transformation by 
inducing apoptosis. In contrast, in late stages of tumor progression, tumor cells can 
become resistant to the growth-inhibitory effects of TGF-ß due to inactivation of the TGF-
ß signaling [75]. Furthermore, TGF-ß can promote cancer progression via increased 
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motility, invasiveness and metastasis [74, 76-77]. The development of resistance to TGF-
ß mediated inhibition of proliferation is frequently observed in various human cancers 
[75].  
 
 
Figure 7. Schematic representation of TGF-ß signaling pathways [71].  
 
 
During EMT, TGF-ß induced Smad signaling regulates the transcription of three 
prominent transcription factor families, the Snail, ZEB and bHLH (helix-loop-helix) 
families, resulting in repression of epithelial marker gene expression and activation of 
mesenchymal gene expression [29, 78].   
Several in vivo and in vitro experiments were performed in order to reveal the possible 
roles of TGF-ß signaling mediators during EMT [78]. For example, Smad2-/- hepatocytes 
appear phenotypically mesenchymal in vivo and their migratory capacities are higher 
compared to wild-type cells, whereas Smad3-/- hepatocytes retain their epithelial 
characteristics [79]. Therefore, it was suggested that TGF-ß driven EMT of hepatocytes 
depends on Smad3 and not Smad2. Smad2 may play an antagonistic role in 
dedifferentiation and EMT of hepatocytes [79]. However, the expression of activated 
Smad2 promotes invasion of spindle tumor cells, compared to the dominant negative 
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form, which has no invasive properties. Consequently, researchers conclude that Smad2 
may promote EMT in vivo [80]. In vitro models revealed an indispensable role of Smad4 
for the transcriptional mechanism that downregulates the expression of E-cadherin in 
response to TGF-ß [81].  
Interestingly, the expression of a novel cytokine, the secreted interleukin-like EMT 
inducer (ILEI), is stimulated by TGF-ß at the translational level [82]. Stable 
overexpression of ILEI caused EMT, invasive growth of carcinomas and metastasis of 
breast cancer models. Actually, the cellular processes and signaling pathways influenced 
by ILEI are still unknown [82].  
In various cancers the suppressive effect of TGF-ß is lost due to either TGFßR mutations 
such as in colorectal cancer, gastric tumors, pancreatic cancers, breast cancer and in T-
cell lymphomas or due to mutated Smads such as in familial juvenile polyposis [8, 83-
85]. However, loss of TGF-ß growth inhibitory effects in cancer cells occurs more often 
downstream of the core TGF-ß signaling pathway. Increased production of TGF-ß is a 
very common feature in various tumors and correlates with the tumor aggressiveness 
[86]. Importantly, the tumor-derived TGF-ß affects various cell types located in the 
surrounding tissue of the tumor as well as the tumor cells themselves (Figure 8) [87].  
 
 
Figure 8. Functions of TGF-ß during cancer progression [87]. 
 
 
TGF-ß establishes an immune-suppressive environment that influences the function of 
immune cells and thus allowing tumor cells to escape immune cells, such as cytotoxic T 
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lymphocytes. In addition, recruitment of new blood vessels towards the tumor tissue 
enables sufficient supply with nutrients and oxygen and facilitates metastasis. This 
process is regulated by tumor secreted TGF-ß which induces the expression of VEGF 
and connective tissue growth factor (CTGF) in both, epithelial cells and fibroblasts [88-
89]. TGF-ß regulates the growth of normal epithelium and early stage tumors, whereas it 
promotes the progression of a carcinoma in situ towards an invasive carcinoma in tumors 
that established TGF-ß resistance but still retained TGF-ß signaling components [87]. 
Frequently, tumor cells achieve an invasive phenotype by undergoing TGF-ß induced 
EMT and thus are more likely to locally infiltrate the surrounding tissue and to spread 
throughout the organism.Several signaling pathways have been shown to be involved in 
TGF-ß induced EMT [29, 78]. TGF-ß is capable to activate Smad- and non-Smad 
signaling pathways [29, 90]. All non-Smad pathways cooperate with TGF-ß/Smad 
signaling in order to orchestrate responses that constitute TGF-ß induced EMT. For 
example, independent of Smad activation, TGF-ß receptors interact with alternative 
signaling effectors, such as mitogen activated protein kinase (MAPK), 
phosphatidylinositol-3’-kinase (PI3K) and small GTPases of the Rho family, which are 
important regulators involved in cell motility, apoptosis and the EMT process  (Figure 6) 
[91-93]. Various observations such as enhanced TGF-ß-induced EMT in the presence of 
mutant Ras, support the hypothesis of an interplay of the Ras-Erk MAP kinase pathway 
and TGF-ß signaling in the induction of EMT [42, 48-49, 94]. In this context, specific 
transcription responses are triggered, leading to the downregulation of E-cadherin and 
the upregulation of N-cadherin and MMP expression [95]. Additionally, hyperactive 
oncogenic Ras leads to enhanced TGF-ß signaling, concomitant by increased autocrine 
TGF-ß secretion and nuclear accumulation of phosphorylated Smads [96]. The activation 
of Erk/MAP kinase signaling seems to be required for TGF-ß induced EMT [95, 97]. In 
addition, TGF-ß signaling induces other players of the EMT process, such as c-Jun 
amino-terminal kinase (JNK) and p38 MAP kinase [78]. The small GTPase RhoA and its 
effector kinase ROCK, which promote stress fiber formation, acquisition of mesenchymal 
morphology and enhanced migration are also activated in response to TGF-ß [98]. 
Moreover, activation of the PI3K/Akt pathway by TGF-ß plays a major role in EMT. Akt is 
a central regulator of pathways involved in cell growth, survival and migration. During 
EMT, activation of the mTOR/S6 kinase  pathway by PI3 kinase/Akt results in enhanced 
protein synthesis [99].  
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Another, highly conserved signaling pathway that cooperates with TGF-ß signaling in the 
elaboration of the EMT response is the Wnt/ß-catenin pathway [29, 78]. Cytoplasmic ß-
catenin, a component of adherens junctions, connects E-cadherin to the cytoskeleton. In 
the absence of Wnt, ß-catenin is phosphorylated by GSK-3ß, a component of the 
adenomatous polyposis coli (APC) destruction complex, leading to its proteasomal 
degradation by E3 ubiquitin ligase [100]. In the case of active canonical signaling, 
induced by binding of Wnt to its corresponding Frizzled receptor, GSK-3ß is inhibited by 
a yet not fully understood mechanism, leading to cytoplasmic accumulation of ß-catenin. 
Subsequently, ß-catenin translocates into the nucleus and interacts with Tcf/Lef 
transcription factors, where they regulate target gene transcription. The cross-talk 
between TGF-ß/Smad signaling and Wnt signaling during EMT has been documented, 
but still remains to be elucidated [101]. However, also Notch signaling is suggested to 
contribute to EMT during tumor progression and cardiac development [78]. Binding of the 
membrane-bound receptor to its ligand presented on the surface of a neighbouring cell, 
triggers the proteolytic cleavage of the Notch receptor, liberating a Notch intracellular 
domain (NIC). The released NIC enters the nucleus where it regulates, together with 
transcription activators, EMT-related gene transcription [29, 78].   
 
2.7. EMT in murine hepatocellular model 
 
To establish a in vitro EMT model, immortalized p19ARF null hepatocytes were isolated 
from murine liver [23, 94]. Due to this genetic alteration the repression of Mdm2 is 
abolished leading to the loss of the growth suppressing functions of p53. These 
immortalized, but non-tumorigenic hepatocytes are termed MIM-1-4. They express liver-
specific marker proteins and are able to reconstitute liver parenchyma after spleen 
injection into Fas-L damaged livers of severe combined immuno deficient (SCID) mice 
[102]. Noteworthy, MIM-1-4 cells have the potential to develop a progenitor phenotype 
that can form hepatocytes or cholangiocytes [103]. MIM hepatocytes were transfected 
with a bicistron expressing constitutively active Ha-Ras and green fluorescent protein 
(GFP) [94]. Accordingly, these defined tumorigenic hepatocytes are termed MIM-Ras. 
Upon TGF-ß treatment MIM-Ras undergo EMT endowing them with metastatic 
properties. These EMT transformed hepatocytes  are referred to as MIM-RT (Figure 9) 
[94]. Importantly, the immortalized MIM-RT hepatocytes which are able to repopulate the 
liver, promote tumor growth upon expression of oncogenic Ras and undergo EMT 
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through the synergism of Ras and TGF-ß [94, 103]. These three hepatic cell lines have 
been employed to establish a murine EMT model. Changes in epithelial plasticity were 
associated with cytoplasmic dislocation or loss of E-cadherin, nuclear accumulation of ß-
catenin as well as the activation of Smad2/3 signaling [104-106]. 
 
 
 
 
 
 
 
 
Figure 9.  Model of hepatic inflammation and liver tumorigenesis. 
 
These findings are of particular relevance since they are known as hallmarks of human 
HCC [94]. Interestingly, about 50% of human HCC display TGF-ß secretion and nuclear 
accumulation of ß-catenin [106-108]. The novel EMT regulator, ILEI (interleukin-like EMT 
inducer), which is able to induce EMT in murine mammary tumor model was tested in 
this hepatic tumor model. Overexpression of ILEI had no detectable effect in MIM-1-4 
cells, but in cooperation with oncogenic Ras, the cells induce and maintain EMT in a 
TGF-ß-independent fashion [82]. In contrast, ILEI overexpression in MIM-C40 cells, 
which are characterized by hyperactivate PI3K, failed to induce EMT, but enabled these 
cells to form tumors [82]. Importantly, another study revealed the essential role of PDGF 
in TGF-ß-mediated EMT of neoplastic hepatocytes [106]. Inhibition of PDGF signaling 
leads to a decrease of cell migration in vitro and tumor suppression in vivo [109]. 
Furthermore the collaboration of oncogenic Ras and ILEI during the fibroblastoid 
conversion of Ras-transformed hepatocytes leads to the upregulation of PDGF signaling 
[109]. Additionally, studies on tumor-stroma cross-talk revealed a crucial role of 
myofibroblasts concerning the TGF-ß-dependent induction as well as the PDGF-
mediated maintenance of EMT [38, 110]. 
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2.8. EMT in murine mammary tumor model  
 
Spontaneously immortalized murine mammary gland cells isolated from midpregnant 
mice retain complete epithelial polarization [82]. These non-tumorigenic epithelial cells 
are termed EpH4. Upon TGF-ß treatment, EpH4 cells enter cell cycle arrest and undergo 
apotosis. After transformation with oncogenic hyperactive Ras, the resulting EpRas cells 
retain full epithelial polarity but become tumorigenic [82]. In the presence of TGF-ß, 
EpRas cells undergo complete EMT in vivo, endowing them with metastatic properities. 
These cells, named Ep-XT are characterized by an fibroblastoid phenotyp, accompanied 
by the loss of epithelial markers, such as E-cadherin and ZO-1 and the upregulation of 
mesenchymal markers, such as vimentin [82]. In vivo studies demonstrated that EpRas 
cells undergo EMT in response to TGF-ß, which is stabilized by an autocrine TGF-ß loop 
[43, 80]. TGF-ß-induced EMT was accompanied by upregulation of PDGF ligands and 
receptors, thus leading to PI3K activation and pro-survival signals [111]. Additionally, it 
was shown that Ras-dependent MAPK pathway hyperactivation in EpH4 cells (EpS35) is 
essential for EMT and metastasis. In contrast, a Ras-induced, hyperactive PI3K pathway 
(EpC40) was required to accelerate tumor growth and to prevent apoptosis, but could not 
cause EMT [82].   
Recently, expression profiling of polysome-bound mRNA was performed in order to 
molecularly characterize the EMT phenotyp and to reveal novel putative EMT regulators 
[112]. The cytokine ILEI, a facultatively secreted protein was identified within this study to 
be translationaly upregulated in EMT transformed Ep-XT cells [82]. In the EpH4/EpRas 
model, overexpression of ILEI causes EMT, accelerated tumor growth and metastasis 
upon tail vein injection. RNAi-mediated knockdown of ILEI in EpRas prevents EMT and 
metastasis [82]. Therefore, the experimental observations suggest that ILEI is both 
necessary and sufficient for EMT and late events in metastasis in epithelial cells [82]. 
 
2.9. Initiation of translation 
 
Mechanism of Cap-dependent initiation  
 
Gene expression is regulated at multiple steps including transcription, splicing, mRNA 
transport, mRNA stability, translation, protein modification and protein stability [113-114]. 
In eukaryotes, the regulation at the level of translation plays an important role in various 
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biological processes and events such as stress response, development and 
differentiation, aging and disease [115]. In comparison to transcriptional regulation, the 
translational control of mRNAs allows rapid changes in the abundance of specific 
proteins. Therefore it enables an immediate response to new cellular conditions such as 
cellular stress due to nutrient deprivation. The process of translation is a sequence of 
highly conserved steps namely initiation, elongation, termination, and ribosome recycling 
[113]. Initiation of translation by ribosome recruitment is the rate-limiting step of protein 
synthesis and thus an effective target for regulatory mechanisms to control the process 
[115].  
The ribosome recruitment to the mRNA in the cytoplasm is mediated by a large number 
of eukaryotic initiation factors (eIFs) (Figure 10) [113, 116]. Initially, the heteromultimeric 
complex eIF4F, consisting of cap-binding protein eIF4E, the RNA helicase eIF4A and 
eIF4G, recognizes the cap structure located at the 5´ terminus (m7GpppN) of the mRNA. 
eIF4G serves as scaffolding protein that bridges the whole eIF4F complex via eIF3 with 
the small ribosomal subunit. eIFA, promoted by eIF4B and eIF4H, unwinds secondary 
structures within the 5´-untranslated region (5´-UTR) in order to facilitate the binding of 
the 43S preinitiation complex [113]. This 43S preinitiation complex contains the 40S 
ribosomal subunit associated with eIF3, eIF1A and the ternary complex of eIF2, GTP and 
the methionyl-initiator tRNA. Once bound to the mRNA, the preinitiation complex starts to 
scan along the 5´-UTR up to the first start codon (AUG). Start codon recogition by codon-
anticodon base-pairing triggers the hydrolysis of eIF2-bound GTP, the dissociation of the 
initiation factors and the subsequent binding of the 60S ribosomal subunit to form the 
functional 80S ribosomal complex. The 80S translation-competent ribosome initiates 
protein synthesis [113, 115, 117].  
However, certain features of the 5´-UTR are known to interfere with the ribosomal 
scanning process. Long GC-rich and highly structured RNAs reduce the ribosomal 
scanning efficiency by inhibiting the migration of the 43S preinitiation complex along the 
5´-UTR [118-119]. Several cap-dependent mechanisms to overcome such limitations 
have been described in various organisms [120-121]. Strong secondary structures which 
can not be disintegrated by the eIF4A helicase may be bypassed by skipping these 
segments, a process termed ribosome shunting in diverse viruses. The mechanism of 
reinitiation enables a second open reading frame (ORF) located within the same mRNA 
to be translated after translation of the first ORF. Thereby the 40S ribosomal subunit 
keeps attached to the mRNA, ready for scanning a new start codon [118-119, 122]. 
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Figure 10.  Initiation of translation in eukaryotes [116]. 
 
 
Translational regulation 
 
The regulation of translation is essential for stress response, cell growth, proliferation 
and differentiation [115]. Thus the translational control machinery depends on extrinsic 
and intrinsic signal molecules such as growth factors, cytokines and ECM proteins which 
modulate various signaling pathways within the cell. These signaling pathways establish 
a complex network that tightly regulates the activity of specific translation initiation factors 
and control protein synthesis [115, 120-121]. An extensively used mechanism in 
eukaryotes to control the rate of translation involves the cap-recognition process. The 
key player of this process is the mRNA cap-binding protein eIF4E which is the rate 
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limiting factor of the eIF4F complex. The availability of active eIF4E is regulated by two 
distinct mechanisms [122]. Firstly, the assembly of eIF4E with eIF4G within the eIF4F 
complex is inhibited by members of a family of heat stable repressor proteins, termed 
eIF4E-binding proteins (4E-BPs). In detail, hypophosphorylated 4E-BPs compete with 
eIF4G for a shared binding site on eIF4E and consequently inhibit cap-dependent 
translation. In contrast, phosphorylation of 4E-BPs weakens the interaction with eIF4E, 
and thereby enables cap-dependent translation. Secondly, upon mitogenic and/or stress 
stimuli, eIF4E is phosphorylated by Mnk1 and 2 downstream of Erk and p38 MAPK 
signaling. Importantly, phosphorylation of eIF4E directly correlates with translation rates 
[121-122]. Another well-documented mechanism to downregulate protein synthesis 
involves eIF2 [115, 122]. eIF2 associates with GTP and Met-tRNA in order to transfer the 
initatior tRNA to the 40S subunit. At a later step during the initiation process, after GTP 
hydrolysis, the eIF2-GDP complex is released. Before eIF2 can promote a new round of 
translation initiation, the remaining eIF2-GDP requires an exchange for GTP, a reaction 
catalyzed by eIF2B. Phosphorylation of the eIF2α subunit stabilizes the eIF2-GDP-eIF2B 
complex and inhibits the turnover of eIF2B. Induction of PKR by interferon (IFN)-γ and 
TNF-α causes potent phosphorylation of eIF2α, a known mechanism which is important 
for the regulation of cell growth and apoptosis [115, 123].  
Generally, Ras and PI3K are two major pathways which mediate growth factor, hormone 
or cytokine dependent translational alterations. Ras signaling activates the MAP kinases 
Erk1/2, which in turn activate the eIF4E kinases Mnk1 and 2, leading to an increase of 
translational initiation [115, 123]. A critical kinase that phosphorylates 4E-BPs is 
mammalian target of rapamycin (mTOR) [124-125]. mTOR is a downstream kinase of 
PI3K/AKT signaling which is responsible for the phosphorylation of several substrates 
relevant for translation, including S6 kinases (S6Ks). Phosphorylated S6Ks activate S6 
ribosomal proteins which stimulate general translation. Prominent inhibitors of mTOR are 
PTEN and rapamycin [115, 123, 125].  
 
Mechanism of Cap-independent initiation 
 
The majority of mRNA translation in eukaryotic cells is initiated via cap-dependent 
ribosomal scanning mechanism. Nevertheless, under certain conditions such as cellular 
stress, proteins that are involved and required for cap-dependent translation initiation are 
compromised due to protein modifications or degradation [122]. In order to enable a 
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continous protein synthesis under stress conditions, mRNA translation relies on an 
alternative initiation mechanism [115]. This cap-independent initiation process is directed 
by a complex RNA structural element referred to as internal ribosome entry site (IRES) 
[115, 120-121, 126-128]. This structural motif, located within the 5´-UTR, enables the 
ribosome to bind directly upstream of the start codon and to initiate translation by 
bypassing cap-dependent ribosome scanning. The first IRES was discovered in 1988 
during studies of poliovirus and encephalomyocarditis virus (EMCV) [129-131]. Since 
then, the list of viral and cellular mRNAs harboring an IRES in the 5´-UTR is still growing 
[127, 132-133]. Generally, IRESs allow maintenance of translation of certain mRNAs 
under conditions of reduced cap-dependent translation. Besides, the involvement of 
mRNAs containing IRES elements in apoptosis, angiogenesis, development, 
differentiation and cell cycle progression emphasizes important functions in cell 
physiology [115, 122-123, 129].  
 
Features of IRES 
 
IRESs are phylogenetically conserved structures that are often found in long GC rich and 
highly structured 5´-UTRs (Figure 11) [118-119, 122]. However, actually no universally 
conserved IRES sequence or structure has yet been identified. Therefore, scientists 
agree that ´diverse´ is the word that best describes IRES structures. Existing functional 
data in combination with structural information reveal a rich structural diversity of viral 
IRES RNAs supporting the idea of functional diversity. The Dicistroviridae intergenic 
region (IGR) IRES presents the most highly structured yet identified IRES [134]. This 
specific and compact three-dimensional structure that does not require any initiation 
factor and operates as an all RNA-based ribosome recruitment apparatus [135]. A 
prefold IRES conformation binds and actively manipulates both ribosomal subunits, 
possibly by mimicking a hybrid state tRNA, and directs translation initiation. In contrast to 
the IGR IRES, the hepatitis C virus (HCV) IRES additionally binds to eIF3, and requires 
initiator tRNA, eIF2, and GTP hydrolysis to initiate translation [134]. Detailed studies 
showed that the HCV IRES interacts with different components of the translation initiation 
machinery. Another class of viral IRESs does not fold globally compact structures but 
retains some conformational flexibility. Typically, these less-structured IRESs require 
various eIFs and IRES-trans acting factors (ITAFs) to recruit the ribosome [136-138]. 
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Figure 11. Examples of viral and cellular IRES secondary structures. (a) Plautia stali intestine virus 
(PSIV) IGR IRES, (b) HCV IRES, (c) FMDV IRES, (d) c-myc IRES, (e) Human immunodeficiency virus-
1 (HIV-1) gag-IRES, (f) PSIV 5′ IRES, the black line indicates a proposed pseudoknot interaction 
[118]. 
 
 
 
ITAFs are not components of the canonical translation initiation machinery but essential 
proteins for the function of many IRESs. The structural integrity of IRES elements may 
be supported by ITAFs. Together, it is suggested that ITAFs are a part of a multi-
component ribonucleoprotein (RNP) complex that enables and directs ribosome 
recruitment to the mRNA. However, the mechanisms by which ITAFs facilitate ribosomal 
recruitment is still poorly understood [136-137].  
Cellular IRESs are characterized by a great variability in length, sequence and 
secondary structure [118]. The length ranges from 60 to 1000 nucleotids (nts), although 
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also 22 nts long, full active elements have been described. Structurally, cellular IRESs 
vary strongly from viral ones, but employ similar ITAFs. For example, some ITAFs that 
were initially identified in a viral context are also used by cellular IRESs including 
polyprimidine tract binding protein (PTB), heterogeneous nuclear ribonucleoprotein A1 
(hnRNP-A1), La and upstream of N-ras (UNR) [136-138]. However, it should be 
mentioned, in some cases that ITAFs such as PTB are inhibitory to IRES function [139]. 
Numerous cellular mRNAs harboring an IRES have been already identified and 
associated with various physiological important processes such as differentiation, 
proliferation and angiogenesis [137, 140]. The observation that ITAFs can induce 
structural changes in cellular IRESs suggests that changes in expression and subcellular 
localization of specific ITAFs enable IRES-containing transcripts to respond precisely to 
changing cellular conditions [138]. Under specific cellular conditions such as stress, 
protein distribution and protein levels are altered, thus affecting structural state and 
activation of a subset of cellular IRESs [122, 137, 140].  
 
Biological significance of internal initiation  
 
IRES-mediated translation initiation represents an alternative mechanism to cap-
dependent translation initiation in a wide range of cellular processes [118, 120, 127, 140-
141]. Observations suggest that IRES-containing mRNA transcripts are predominantly 
translated via internal initiation under conditions of reduced cap-dependent translation 
due to e.g. stress, apoptosis or viral infections. In some cases such as for fibroblast 
growth factor 2 (FGF2), the balance of cap-dependent and IRES-mediated protein 
expression is determined by the availability of ITAFs and regulatory eIFs and the activity 
of other cis regulatory elements [139]. The presence of ITAFs and other regulatory 
factors has been confirmed to be essential for the activity of some cellular IRESs in in 
vitro studies [138]. Thus, these IRES-containing transcripts show general low cap-
dependent and –independent translation under normal conditions, but are inducible in 
response to changing cellular conditions. Interestingly, internal initiation is mainly 
triggered during cellular processes such as differentiation, proliferation, angiogenesis 
and apoptosis or under conditions when cap-dependent translation is diminished such as 
heat shock, hypoxia or nutrient deprivation [122]. It is assumed that IRES-mediated 
translation control might regulate the cellular response in transient stress conditions in 
order to avoid programmed cell death [137].  
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Figure 12. The proposed model for IRES-dependent translational regulation of cell death [142]. 
 
However, cap-independent translation has been implicated in the regulation of apoptosis 
itself (Figure 12) [126, 141-142]. During apoptosis, several factors required for the cap-
dependent translation are reduced due to caspase cleavage. Under these 
circumstances, IRES-mediated translation displays an essential alternative method to 
synthesize proteins involved in the apoptotic process. Some important regulatory 
proteins related to apoptosis include c-myc, X-linked inhibitor of apoptosis (XIAP), 
(DAP5) and apoptotic protease activating and factor 1 (ApaF1) [126, 141, 143-144]. 
Furthermore, IRES-mediated initiation is involved in the synthesis of Bag-1 during the 
recovery phase of heat shocked cells, or the synthesis of alpha subunit of hypoxia-
inducible factor-1 (HIF-1α) and FGF2, both growth factors promote blood vessel 
formation in hypoxic cells via IRES-mediated upregulation of VEGF [122-123, 126, 139, 
145-146]. These above listed proteins are only few examples, which support the idea 
that cellular IRESs may be evolved as an alternative regulatory mechanism to respond 
precisely to certain states of the cell such as stress.  
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Internal initiation during carcinogenesis  
 
The fact that IRES elements are observed in transcripts corresponding to regulatory 
proteins confirms an important function of internal translation initiation in many cellular 
processes [136]. The relevance of IRES-mediated translation in cancer is particularly 
provided by c-myc, one prominent pro-oncogene that is frequently transcriptional 
deregulated in many cancers. Interestingly, oncogenic gain-of-function provided by a C-T 
mutation located in the IRES of c-myc, correlates with increased c-myc translation in 
cells derived from patients with multiple myeloma [143, 147]. Futhermore, various 
proteins that contain an IRES element in the 5´-UTR are associated with carcinogenesis 
including survival factors such as Bag-1 and growth factors such as FGF2, PDGF and 
VEGF [122-123, 126, 139, 145-146]. Many genes that drive tumorigenesis are not 
mutated, but are translationally deregulated. This observation is supported by the fact 
that central signaling pathways of translation regulation, namely Ras/ERK and 
PI3K/Akt/mTOR pathway are frequently activated in tumors [148]. Both pathways 
regulate protein synthesis by activating the ribosomal S6 protein and / or translation 
initiation factors for the ribosome recruitment to the mRNA. In tumors, Ras is frequently 
activated by mutation, whereas enhanced PI3K signaling is provided by the inactivation 
of the tumor suppressor PTEN. eIF4E, a rate limiting factor of cap-dependent translation 
initiation is a major target of both signaling pathways. eIF4E is activated by 
phosphorylation as well as by the inactivation of its inhibitory counterpart, the 4E-BP. 
Under normal conditions, mRNAs may have to compete for the availability of eIF4E [24, 
59, 123-124, 149-150]. Generally, it is supposed that short unstructured 5´-UTRs are 
more likely to become translated than those with long, GC rich and highly structured 5´-
UTRs such as IRES containing mRNA transcripts. Experimental overexpression of eIF4E 
increases cap-dependent translation in various types of tumors including breast, head 
and neck, bladder, liver and colon cancers [151]. Importantly, elevated eIF4E levels 
selectively enhances the translation of IRES-containing and metastasis-related mRNAs 
such as VEGF, ornithine decarboxylase (ODC) or FGF-2. Accordingly, it was 
demonstrated that overexpression of eIF4E induces malignant transformation in 
epithelial cells. Another study could connect phosphorylated eIF4E with tumor cell 
survival. In a mouse model of B cell lymphoma it was shown that activated eIF4E targets 
the antiapoptotic protein Mcl-1, and thus suppresses apoptosis [151]. Enhanced eIF4E 
activity might also influence the process of epithelial to mesenchymal transition (EMT), a 
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frequent event in late stage tumorigenesis [151-152]. Although, it was shown that 
overexpression of eIF4E is required for the induction of EMT [123], little is known about 
translational regulation and the impact of IRES mediated translation during EMT. 
Interestingly, siRNA-mediated downregulation of eIF4E expression could revert the Ras-
oncogene transformed phenotype in a cell culture model [153]. The transforming activity 
of eIF4E can be in part explained by its ability to maintain the IRES-mediated expression 
of several oncogenes under stress conditions. In many cancers the amount of eIF4E is 
elevated, supporting the idea of an indispensable role during tumor progression [123].  
 
Translational control by the 3´-UTR 
 
The 3´-UTR with its proximity to the termination codon and the poly-A tail offers a 
diversity of regulatory mechanisms [113, 154]. For example, polyadenylation signals 
within the 3´-UTR regulate mRNA stability, whereas other signals regulate the subcellular 
localization of specific transcripts. Additionally, processed miRNAs, loaded into RNA-
induced silencing complexes (RISC), are able to target specific miRNA-complementary 
sites within the 3´-UTR and inhibit protein expression [115, 155-157]. However, the 3´-
UTR has been demonstrated to communicate with the 5´-cap-complex via the interaction 
of PABP with the N-terminal part of eIF4G in order to modulate cap-dependent 
translation. Little is known about the involvement of the 3´-UTR on IRES-mediated 
translation [113, 144]. 
 
2.10. Laminin B1 in tumor progression 
 
Laminin B1 (LamB1) is one of the three ß subunits that form together with α and γ chains 
several heterotrimeric laminin isoforms which perform diverse functions in different 
tissues [158]. The α-, ß- and γ-polypeptide chains build a triple-helical coiled structure 
that is organized by disulfide bridges, resulting in a cruciform shaped glycoprotein 
composed of three short arms, each formed by a different chain, and one main arm 
consisting of all three chains. LamB1 belongs to the extracellular matrix (ECM) proteins 
and is involved in many ECM - cell interactions, thus affecting multiple cellular processes 
such as cell adhesion, migration, proliferation and differentiation [159]. During tumor 
invasion and metastasis malignant cells cross the basement membrane in order to leave 
the primary tumor, to invade surrounding tissue and to intravasate into the vascular 
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system. The interaction of malignant cancer cells with LamB1, which is a main 
component of the basement membrane, is a key step in cell migration. Notably, a study 
with neoplastic cells revealed that the expression of the 67 kDA Laminin binding protein, 
a receptor that interacts with the LamB1 subunit, is enhanced and directly correlates with 
invasiveness [159]. Therefore LamB1 emphasizes its particular interest in cancer 
progression. Laminin signaling is mediated by integrins and its corresponding laminin 
receptor, leading to the activation of central signaling pathways such as MAPK and PI3K 
[160]. Both pathways are known to be involved in EMT related events such as 
microfilament rearrangements or regulation of cell growth and differentiation. In a recent 
study, expression profiling was performed in order to determine translationally controlled 
mRNAs during hepatocellular EMT [161]. Among the 84 translationally upregulated 
mRNAs, LamB1 was detected. Bicistronic reporter assays provided first evidence that 
the 5´-UTR of LamB1 contains a bona fide IRES that mediates the translational 
regulation during stress conditions and neoplastic progression of hepatocytes [110].  
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2.11. Working Hypothesis 
 
Concerning the ECM protein LamB1, data of previous monocistronic reporter assays 
revealed a strongly enhanced reporter activity of constructs carrying the LamB1 5´-UTR, 
thus proposing an initiation mechanism alternative to ribosomal scanning [110]. 
Additionally, analysis of the LamB1 5´-UTR based on Zukers algorithm predicts a highly 
stable secondary structure with a minimal free energy of -154 kcal / mol that may impair 
cap-dependent translation. In agreement with existing data, experiments with bicistronic 
reporter constructs showed an activation of LamB1 protein expression via internal 
ribosome initiation upon EMT in murine MIM-Ras hepatocytes and in human SW480 
colon carcinoma cells (Figure 13) [110]. Therefore, we propose that an IRES motif, 
located in the 5´-UTR, is essentially required for the cap-independent translation of the 
LamB1 mRNA. Additionally, we suggest a possible role of the LamB1 3´-UTR in 
regulating IRES-dependent translation. Furthermore, we suppose that MAPK and PI3K 
signaling is involved in IRES-mediated LamB1 translation in the murine hepatic EMT 
model. 
 
Figure 13.  LamB1 5´-UTR upregulates reporter gene expression in murine and human cancer [110]. 
 
Recently, expression profiling was performed in order to identify EMT-specific genes. 
The interleukin like EMT inducer (ILEI), a cytokine-like secreted protein was revealed to 
be exclusively upregulated at the translational level [82]. Furthermore it was shown that 
ILEI is both necessary and sufficient for EMT, tumorigenesis and metastasis of epithelial 
cells [82, 162]. Besides the assumption that the leader region of ILEI mRNA confers cap-
independent translation, we propose a regulatory role of the 3´-UTR on translational 
efficiency of cells undergoing EMT. 
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2.12. Aim of study 
 
The general aim of the project is the identification of the cis-acting IRES motif of LamB1 
mRNA. Therefore we aimed to determine the minimal sequence of the IRES motif which 
mediates cap-independent translation. In order to localize the IRES sequence , we 
established bicistronic reporter constructs carrying deletion fragments of the LamB1 5´-
UTR. To accomplish our tasks we used the well studied malignant murine MIM-Ras 
hepatocytes. Furthermore, a monocistronic assay using the Firefly Luciferase (Luc) 
reporter gene was employed to investigate a regulatory role of the 3´-UTR of LamB1 in 
malignant MIM-Ras and metastatic MIM-RT hepatocytes in the context with IRES-driven 
translation. Within this experimental setup, we additionally examined a possible role of 
the ILEI 3´-UTR on translational efficiency in a murine breast cancer model. In order to 
examine LamB1 translational regulation in a human EMT model, we performed a 
monocistronic reporter assay in human colon cancer cell lines. To complete our 
investigations we elucidated the molecular mechanisms involved in IRES-mediated 
translation by pointing out the crucial role of the MAPK and PI3K signaling during EMT.  
 
 
 
 
 
 
 
 
 
 
 
 
 to determine the minimal sequence of the IRES motif which 
mediates cap-independent translation 
 to investigate the translational upregulation of Laminin B1 in 
human colon cancer cells 
 to examine the regulatory role of the 3´-UTR of LamB1 and ILEI 
 to elucidate the signaling involved in IRES-mediated translation  
Aims of the study
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3. Materials and Methods 
 
 
3.1. Cell culture 
 
The p19ARF-/- murine hepatocyte cell lines MIM-1-4 and MIM-Ras were seeded on rat tail 
collagen-coated cell culture dishes and grown in RPMI 1640 plus 10% fetal calf serum 
(FCS) and 1% antibiotics [103]. Medium for MIM-1-4 cells was additionally supplemented 
with 40 ng/ml recombinant human transforming growth factor (TGF)α (Sigma, St.Louis, 
USA), 30 ng/ml recombinant human insulin-like growth factor II (IGF-II, Sigma, St. Louis, 
USA) and 1,4 nM insulin (Sigma, St.Louis, USA) [103]. Malignant epithelial MIM-Ras 
cells were established by the stable retroviral transmission of the parental MIM-1-4 cells 
with oncogenic v-Ha-Ras [94]. Fibroblastoid MIM-RT cells, derived from MIM-Ras cells 
after long term treatment with TGF-ß1, were additionally supplied with 1 ng/ml human 
TGF-ß1 (R&D Systems, Minneapolis, USA) as described  previously [94].  
The murine mammary cell lines EpH4, EpRas and Ep-XT were cultured in Dulbecco´s 
Modified Eagle Medium (DMEM) plus 15% FCS and 1% antibiotics. Epithelial EpH4 cells 
tansformed with oncogenic v-Ha-Ras are termed EpRas cells, which retain full epithelial 
polarity [43]. Upon TGF-ß1 (1 ng/ml human TGF-ß1) treatment, these cells undergo EMT 
in collagen gels and show a fibroblastoid morphology, which is stabilized by autocrine 
TGF-ß signaling [82]. The human colon carcinoma cell lines HT-29, SW480 and SW620 
were grown in DMEM supplemented with 10% FCS and 1% antibiotics.  
All cells were kept at 37°C and 5% CO2 and routinely screened for the absence of 
bacteria and mycoplasma.  
 
3.2. Cloning of plasmids 
 
Bicistronic reporter constructs carrying LamB1 5´-UTR deletions 
 
Deletions of the LamB1 5’-untranslated region (UTR) were generated by PCR using the 
pLamF vector as template. Three different  forward primer containing a NheI restriction 
site were designed which targeted the nucleotide positions 155, 200 and 235 within the 
LamB1 5´-UTR. The reverse primer, which contains a XhoI restriction site was positioned 
at the 3´-end of the LamB1 5´-UTR at nucleotide 335. Primers were designed according 
to GenBank sequence NM_002291. The generated amplicons were cloned into the 
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multiple cloning site (MCS) of a bicistronic reporter construct (p-ßgal-CAT) using the 
NheI and XhoI restriction sites. The resulting p-ßgal-155-CAT, pßgal-200-CAT and 
pßgal-253-CAT deletion contructs, the empty reporter construct (p-ßgal-CAT), a 
construct containing a 162bp long X-linked inhibitor of apoptosis (XIAP) 5’-UTR fragment 
(p-ßgal-XIAP-CAT) and the full length LamB1 5´-UTR (p-ßgal-Lam-CAT) were each 
transformed into E.coli GT116. The bicistronic reporter construct carrying the minimal 
IRES sequence of XIAP served as positive control and was a gift from M. Holcik.  
 
Primer for LamB1 5’-UTR deletions: 
 
5´-UTR_155_fw 5´-CCTAGCTAGCAGGCGCCTCCCT-3´ 
5´-UTR_200_fw 5´-CCTAGCTAGCTTCTTTGGGCTCGGG-3´ 
5´-UTR_253_fw 5´-CCTAGCTAGCGGAAGACGGGAAG-3´ 
5´-UTR_335_rv 5´-GCGCTCGAGGCCGGCTCCCT-3´ 
 
 
Monocistronic reporter constructs carrying the 5´-UTR and the 3’-UTR of LamB1 
mRNA 
 
Monocistronic reporter constructs carrying either the LamB1 5´-UTR upstream (pLam-F) 
or the LamB1 3´-UTR downstream (pF-Lam) of a firefly luciferase reporter gene were 
established. Additionally, a construct that harbors both the LamB1 5´-UTR and the 3´-
UTR was generated (pLam-F-Lam). SW480 cDNA was used as template to amplify the 
LamB1 3´-UTR by PCR. PCR primers contained XbaI restriction site and were designed 
according to the GenBank sequence NM_002291. The amplified 3’-UTR was cloned into 
the XbaI restriction site of the pLam-F vector resulting in pLam-F-Lam containing the 
LamB1 5’UTR upstream as well as the 3’UTR downstream of the firefly reportergene. 
Subsequently, the monocistronic construct pF-Lam was generated by excising the 
LamB1 5´-UTR from the pLam-F-Lam vector using NheI and XhoI restriction sites. The 
pLam-F monocistronic reporter construct was already previously generated [110]. A 
monocistronic vector exclusively harboring the firefly luciferase reporter gene served as 
negative control and was together with pLam-F, pF-Lam and pLam-F-Lam transformed 
into E.coli GT116. 
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Primers used: 
 
3´-UTR_LamB1_fw 5´-TCTAGATAGCACATGCTTGTAA-3´ 
3´-UTR_LamB1_rv 5´-TCTAGAACAAAAGCACTGTACT-3´ 
 
 
Monocistronic reporter constructs carrying the 3´-UTR of ILEI mRNA 
 
The ILEI 3´-UTR was amplified from SW480 cDNA. PCR primers contained XbaI 
restriction sites and were designed according to the GenBank sequence NM_014888.2. 
The amplified ILEI 3´-UTR was cloned into the XbaI site of the monocistronic pF vector 
downstream of the firefly luciferase reporter gene, resulting in pF-ILEI. The generated 
constructs as well as the empty control vector pF were transformed into E.coli GT116.  
 
Primers used: 
 
3´-UTR_ILEI _fw 5´-TCTAGAGAAAGCGCACTTTCA -3´ 
3´-UTR_ILEI_rv 5´-TCTAGACAAAGCAAAACCAAGAG-3´ 
 
Ligation 
 
Before carrying out the ligation reaction, purified linearized vectors were 
dephosphorylated (CIP-reaction) to prevent religation and to facilitate insertion of the 
purified amplicon. 
 
CIP-reaction 
10 µl purified DNA, 10 µl 10x Dephosphorylation buffer, 77,5 µl ddH2O and 2,5 µl calf 
intestinal phosphatase (CIP [20 U/µl]) were mixed together in a microcentrifuge tube and 
incubated for 30 minutes at 37°C. In order to boost dephosphorylation, another 2,5 µl 
CIP were added and the mixture was incubated for additional 45 minutes at 55°C. 
Subsequently, the phosphatase was heat-inactivated by incubating for 15 minutes at 
85°C. Dephosphorylated plasmids were purified using a DNA purification kit (QIAGEN, 
Hilden, Germany) according the manufacturers instructions. 
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Ligation 
50-100 ng vector DNA were mixed with insert at different molar ratios (1:1, 1:2, 1:4) and 
incubated over night at 16°C or over weekend at 4°C. 
 
Vector DNA: 50 – 100 ng 
Insert DNA: 2 – 5 fold amount of the vector DNA 
 
x µl vector-DNA 
1 µl 10x Ligation Buffer 
x µl Insert 
x µl H2O 
1 µl T4 Ligase 
10 µl final volume 
 
All cloned plasmids were sequenced. 
 
3.3. Microbiology 
 
Preparation of E.coli for transformation 
 
50 ml E.coli - lysogeny broth (LB) suspension (OD600=0,375) was centrifuged for 7 
minutes at 3000 rpm at 4°C and obtained pellet was resuspended into 10 ml 0,1 M CaCl2 
solution. E.coli suspension was centrifuged for 5 minutes at 2500 rpm at 4°C and pellet 
was again resuspended into 10 ml 0,1 M CaCl2 solution and then kept on ice for 30 
minutes. Afterwards, E.coli suspension was centrifuged for 5 minutes at 2500 rpm at 
4°C. The generated pellet was resuspended into 2 ml 0,1 M CaCl2 solution, snap frozen 
in liquid nitrogen and stored at -80°C. 
 
Transformation of E.coli 
 
A 3 or 5 µl (10 ng) aliquot of vector DNA was resuspended into 100 µl of CaCl2 -
competent E.coli GT116 and kept for 10 minutes on ice. Cells were heat shocked at 
42°C for 2 minutes and then placed back on ice. 1 ml LB -medium was added to 
regenerate E.coli. Cells were incubated for 1 hour at 37°C, shortly centrifugated at 110 g 
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and the supernatant was poured off. The cell pellet was resuspended in the remaining 
(~100 µl) supernatant, plated on LB/ampicillin plates and incubated at 37°C over night. 
All plasmids expressed ampicillin resistance as selection marker. 
 
Plasmid DNA preparation 
 
Single E.coli colonies were picked and grown in 3-5 ml LB/ampicillin-medium at 37°C for 
3 hours by moderate shaking. 100 µl of these pre-cultures were inoculated in 200-500 ml 
LB/ampicillin and cultured at 37°C over night by moderate shaking. The plasmid DNA 
was isolated using a QIAfilter Plasmid Midi/Maxi Kit (QIAGEN, Hilden, Germany) as 
recommended by the manufacturer. The integrity of isolated DNA plasmids was 
confirmed by restriction analysis and separation of DNA fragments in an 1% 
agarose/ethidium bromide (EtBr) -gel. 
 
Restriction digests of plasmids 
 
Preparative plasmid digests 
Reactions using DNA restriction enzyms were performed to excise DNA sequences from 
plasmids or to linearize plasmids for subsequent ligation reactions. Therefore, 30 µl 
vector DNA, 10 µl restriction buffer, 54 µl H2O and 6 µl restriction enzyme were mixed 
and incubated for 2 – 4 hours at 37°C. For some double digests, reactions were 
optimized by altering digest conditions, or a step-by-step digestion was performed by 
inclusion of an additional purification step using QIAgen purification kits as 
recommanded by manufacturer (Fermentas, Burlington, Canada). Afterwards, the 
digested plasmids were separated via agarose gel electrophoresis. DNA fragments of 
the correct sizes were cut out with a scalpel and the DNA was purified using a Gelex 
purification kit (QIAGEN, Hilden, Germany).  
 
Control plasmid digests 
Control restriction analysis was performed to check the size and orientation of cloned 
DNA fragments. In general, 2 µl vector DNA, 1 µl restriction buffer, 6 µl H2O were 
incubated with 0,5 µl restriction enzyme for 1 – 2 hours at 37°C. DNA fragments were 
separated by agarose gel electrophoresis and visualized by EtBr staining.      
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3.4. Agarose gel electrophoresis 
 
Electrophoresis 
Generally, 1% agarose gels were prepared. In case of smaller DNA fragments with a 
size < 300 bp, 2% agarose gels were employed. Agarose was dissolved in 1 x TAE (40 
mM Tris-acetate, 1 mM EDTA) by heating up in the microwave. After cooling down to 
approximately 60°C, EtBr (1 µg/ml) was added. The gel was poured immediately 
afterwards and was allowed to polymerize for 45 minutes before use.  
 
Sample preparation 
DNA was mixed with sample buffer (0,313 M Tris-HCl, pH 6,8; 10% SDS; 0,05% 
bromophenol blue; 50% glycerol) and loaded onto the gel. Gels were run in 1 x TAE 
running buffer at 100 Volt. In the case of a preparative gel, DNA bands were excised with 
a razor blade under UV light. Subsequently, DNA was isolated using a QIAquick Gel 
Extraction Kit (QIAGEN, Hilden, Germany).  
 
 
3.5. Polymerase chain reaction (PCR) 
 
 
PCR to generate cloning fragments 
PCR was employed to generate amplicons carrying at both ends restriction sites for 
cloning. cDNA or linearized plasmids served as templates for amplification.  
 
First PCR program example: 
2x (95°C 2´/ 56°C 1´10´´/ 72°C 1´55´´) 
2x (95°C 50´´/ 54°C 52´´/ 72°C 1´40´´) 
30x(95°C 42´´/ 52°C 45´´/ 72°C 1´10´´) 
72°C 10´/ 8°C 
 
 
PCR product received from first round of PCR was then used as template in a further 
PCR in order to generate high amounts of amplicon. The applied Taq beads (GE 
Healthcare, Buckinghamshire, UK) contained all substances needed for PCR reaction. 
 
Second PCR program example: 
2x (95°C 2´/ 56°C 1´10´´/ 72°C 1´55´´) 
2x (95°C 50´´/ 54°C 52´´/ 72°C 1´40´´) 
36x (95°C 42´´/ 52°C 45´´/ 72°C 1´10´´) 
                        72°C 10´/ 8°C 
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First PCR                                                       Second PCR 
Template / PCR 
product 
1 µl 
Pfu-Buffer 5 µl 
dNTPs (mM) 1 µl 
Primer Mix (30 nmol) 30 µl 
Pfu-Polymerase 0,5 µl 
H2O 18,5 µl 
Final volume 50 µl 
  
 
Control PCR 
Besides control plasmid digestion, the plasmid DNA of transformed E.coli was checked 
directly by control PCR. Only the E.coli suspension containing the plasmid with insert in 
correct orientation provided a PCR product with a correct fragment length.  
 
E.coli-suspension 1 µl
ddH2O 8 µl
Primer Mix (30 nmol) 15 µl
Taq-Bead 1x
Final volume 25 µl
 
PCR program example: 
95°C 5´ 
2x (95°C 2´/ 60°C 1´10´´/ 72°C 1´55´´) 
2x (95°C 50´´/ 58°C 52´´/ 72°C 1´40´´) 
36x (95°C 42´´/ 52°C 45´´/ 72°C 2´) 
72°C 10´/ 8°C 
 
Primer pair used for verification of p-ßgal-155/200/253-CAT: 
 
p-ßgal-155/200/253-CAT_fw 5´-GCGTCTTCTCCACTCCTCTG-3´ 
p-ßgal-155/200/253-CAT_rv 5´-CGTAACACGCCACATCTTGC-3´ 
 
 
Primer pair used for verification of pF-Lam: 
 
pF_Lam_fw 5´-TTGCTAACGCAGTCAGTGCTTC-3´ 
pF_Lam_rv 5´-CCTTGTTCACCTCAGCCATT-3´ 
 
 
 
 
 
 
PCR product 5 µl 
ddH2O 5 µl 
Primer Mix  (30 nmol) 15 µl 
Taq-Bead 1x 
Final volume 25 µl 
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3.6. Transient transfection with Lipofectamine Plus™  
 
Transient transfections of different cell lines were performed under the described cell 
culture conditions. 
Cells were seeded on 6-well plates at a density of 3 x 105 cells one day before 
transfection in order to reach a cell confluence of 70%. Lipofectamine Plus™ was used 
for transient transfections as recommended by the manufacturer (Invitrogen, Carlsbad, 
USA). Relative Firefly Luciferase activity of monocistronic plasmids was determined by 
co-transfection of 0,75 µg plasmid and 0,25 µg ß-galactosidase reporter. Together, 1 µg 
vector DNA was mixed with 100 µl unsupplemented medium and 6 µl Plus reagent. In 
parallel, 4 µl Lipfectamine reagent were mixed with 100 µl unsupplemented medium. 
Both mixtures were carefully resuspended and incubated for 15 minutes at room 
temperature. Subsequently, both suspensions were mixed by pipetting gently up and 
down and incubated another 15 minutes at room temperature. Meanwhile, cells were 
washed with 1 x PBS (phosphate buffered saline: 8 g NaCl; 0,2 g KCl; 1,15 g Na2HPO4 
and 0,2 g KH2PO4 in 1 liter H2O) and 800 µl unsupplemented medium were added to 
each well. 200 µl of the incubated DNA-Lipofectamine Plus mixture were dropwise added 
to cells. After incubation of 3 hours at 37°C, cells were washed with 1 x PBS and 
supplied  with 2 ml of fresh medium containing FCS and 1% antibiotics. Transfected cells 
were incubated for 48 hours at 37°C and 5% CO2 before cell lysates were prepared.  
 
ß-Galactosidase assay 
 
The whole procedure was performed on ice. After washing cells with 1x PBS, 200 µl lysis 
buffer (0,25 M Tris/HCl pH 7,5; 0,5% Triton X-100) were added. Cell lysis was performed 
by pipetting up and down. The lysate was subsequently centrifuged at 12000 g for 10 
minutes at 4°C and the supernatant was transferred into a new tube. Extracts were 
immediately used to perform assays or snap frozen in liquid nitrogen and stored at -
20°C. 
To analyze the ß-galactosidase activity, 20 µl cell extract or 20 µl H2O as blank were 
incubated with 268 µl 0,1 M sodium phosphate solution (0,06 M Na2HPO4; 0,04 M 
NaH2PO4; pH 7,5), 88 µl 1x 2-Nitrophenyl-β-D-galactopyranosid (ONPG) (Sigma, N-
1127; 4 mg/ml of ONPG was dissolved in 0,1 M sodium phosphate solution; pH 7,5) and 
4 µl 100 x Mg2+ solution (0,1 M MgCl2; 4,5 M ß-mercaptoethanol) at 37°C for 30 minutes 
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until a faint yellow color developed. Optical density was photometrically measured at a 
wavelength of 420 nm (linear range is 0,2 – 0,8 O.D.). All assays were done in triplicate. 
 
Luciferase reporter assay 
 
Assay buffer was always freshly prepared by mixing 6,28 ml H2O with 2,5 ml 0,1 M 
glycylglycine (Fluka 50199; pH 7,8), 150 µl 1 M MgSO4 and 500 µl 0,1 M ATP (disodium 
salt, Boehringer). The injection buffer consisting of 6 ml H20, 2 ml 0,1 M glycylglycine pH 
7,8 and 2 ml 1 mM luciferin (D-Luciferin Sigma Sodium salt L-6882) was stored at -20°C.  
Cell extracts were generated as described for the ß-galactosidase assay. 50 µl assay 
buffer was mixed with 20 µl cell extract  or water as blank in a 96 well plate  and 
immediately measured with a luminometer (Labsystems, Farnborough, UK). The assay 
was performed in triplicate.  
Luminometer settings were adjusted as follows: The reagent volume of injection buffer to 
be automatically added before each measurement was set to 50 µl. Luciferase activity 
was measured in an integral curve of 10 seconds. The lag time between each 
measurement was set to 1 second. Measured luciferase activities were normalized to the 
corresponding ß-galactosidase values. Results represent the average of three 
independent experiments. 
 
Chloramphenicol acetyltransferase (CAT) ELISA 
 
The quantitative determination of the chloramphenicol acetlytransferase (CAT) activity in 
cell extracts was performed by photometry of Enzyme-linked Immunosorbent Assay 
(ELISA) plates.  
 
Sample preparation for CAT ELISA 
Cell extracts were generated according to the CAT ELISA protocol (Roche, Mannheim, 
Germany). The ß-galactosidase assay and CAT ELISA were performed with the same 
cell extract. Cells were washed 3 x with pre-cooled PBS and lysed with 500 µl CAT 
lysisbuffer per 6-well plate. Cells were subsequently scraped, transferred into 
microcentrifuge tubes and immediately snap frozen in liquid nitrogen and stored at -20°C. 
Frozen cell lysates were thawed up and centrifuged for 15 minutes at 4°C at 10000 g. 
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Supernatants were then transferred into new microcentrifuge tubes and employed for 
CAT and ß-gal assays. 
 
CAT ELISA  
Each prepared sample was measured in duplicate. The working procedure was 
performed according to the CAT ELISA manufacture protocol (Roche, Mannheim, 
Germany). 
 
 
3.7. Western blot analysis 
 
 
Sample preparation for Western blotting  
 
All steps were performed on ice. RIPA+ lysis buffer containing 0,95 ml RIPA buffer (150 
mM NaCl; 50 mM Tris pH 7,4; 0,5% Nadeoxycholate; 1 mM ß-Glycerophosphat pH 7,2; 
1% Nonidet P-40), 50 µl 20x Complete and 17 µl inhibitor cocktail (1 mM NaF; 1 mM 
Na3VO4; 1 mM PMSF; 10 µg/ml Leupeptin; 10 µg/ml Aprotinin) was freshly prepared. 
Confluent cells were washed twice with ice-cold PBS and then lysed with 100 or 200 µl 
RIPA+ buffer. Afterwards, cells were scraped off using a police rubber, resuspended 
several times and transferred into microcentrifuge tube. Subsequently, the cell lysate 
was centrifuged for 10 minutes at 10 600 g at 4°C. The generated supernatant was 
transferred into a new microcentrifuge tube and snap frozen in liquid nitrogen and stored 
at -20°C.  
 
Bradford assay 
 
Bradford assay was performed to determine the protein concentration of cell lysates. A 
standard curve was generated with bovine serum albumin (BSA) dilutions (0,1; 0,2; 0,4; 
1,8; 1,0; 1,2 mg/ml). All samples were diluted (1:10 or 1:20) with cell lysisbuffer  in order 
to receive absorption values inside the linear range. Lysisbuffer served as blank. To 
perform the assay, 2 µl sample dilution, BSA dilution or water were mixed with 98 µl 
Bradford solution in a 96 well plate. Finally, absorption was measured at 595 nm. Protein 
concentrations of the cell lysates were then calculated with the standard curve. 
 
 
‘Translational regulation of Laminin B1 and ILEI during cancer progression’                  Hau Mara                   
 
 50
Western blotting 
 
Protocol 
Western blotting was performed to detect proteins in RIPA+ cell lysates. Protein 
concentrations were determined by Bradford as described. 40 µg protein lysate was 
mixed with 2x sodium dodecyl sulfate (SDS) sample buffer, denaturated for 5 minutes at 
95°C and then loaded onto a 7,5%, 10% or 12% polyacrylamide (PAA) gel. To compare 
protein weights, a prestained marker (Fermentas, Burlington, Canada) was additionally 
loaded on each gel. Separation gels and stacking gels were prepared according to the 
tables below. 
 
 
for separation gels 
 7,5% 10% 12% 
30% PAA  2,5 ml 4,45 ml 5,2 ml 
2 M Tris pH 8,8 1,87 ml 2,5 ml 2,25 ml 
ddH2O 5,63 ml 6,2 ml 4,42 ml 
Total 10 ml 13 ml 12 ml 
45 µl APS (10%); 7,5 µl TEMED were added; gels were overlaid with Isopropanol 
 
for stacking gels 
30% PAA/1% PDA 0,5 ml  
1M Tris pH 6,8 0,5 ml 
ddH2O 3 ml 
Total 4 ml 
20 µl APS (10%); 4 µl TEMED were added 
 
Under denaturing conditions, electrophoresis run for 2 hours at 100 constant voltage 
(Vconst). Afterwards, separated proteins were blotted onto a nitrocellulose membrane for 
1 hour at 400 mA. Nitrocellulose membrane was then washed with H2O and stained with 
Ponceau to visualize proteins. To allow different protein stainings, nitrocellulose 
membrane was cut into parts if needed. Further, all membranes were blocked for 1 hour 
(at room temperature) or over night (at 4°C) with 5% BSA – Tris buffered saline-Tween 
(TBST) (150 mM NaCl; 10 mM Tris pH 8; 10% Tween 20) solution and afterwards 
directly stained with a primary antibody - TBST solution for 2 hours at room temperature. 
After 3x washing with TBST, the membranes were incubated with the secondary 
antibody – TBST solution for 1 hour at room temperature. Membranes were further 
washed for several times to remove the antibodies surplus. Finally, enhanced 
chemiluminescent (ECL) solution (Thermo scientific, Rockford, USA) was added, 
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incubated for 2 minutes and membranes were developed. In the presence of ECL 
solution, the horseradish peroxidase linked to secondary antibody performed an 
enzymatic reaction, which generates luminescence detectable on a X-ray film. The 
observed signal intensity corresponded to the amount of proteins presented in the loaded 
sample. The Actin protein served as loading control in order to ensure that comparable 
protein amounts were loaded. Due to the instability of protein phosphorylations, 
nitrocellulose membranes were first analyzed for the phosphorylated proteins and 
afterwards checked for the unphosphorylated proteins.  
 
Solutions 
2x SDS sample buffer:                   10x Tris / Glycine:                 TBST: 
1 ml Tris / HCL                               30 g Tris                               10 ml 10% Tween in 
5 ml 10% SDS                                144 g glycine                        1 l 1x TBS 
0,5 ml ß-mercaptoethanol              dd H2O to 1 l 
2 ml glycine 
10 mM DTT 
dd H2O to 10 ml 
 
Electrophoresis buffer:                    Blotting buffer: 
100 ml 10x Tris / Glycine                 100 ml 10x Tris / Glycine 
5 ml 20% SDS                                 150 ml Methanol 
final volume 1 l                                 1 ml 20% SDS 
                                                         final volume 1 l 
Western blot stripping  
 
Membranes were incubated with pre-warmed stripping-buffer for 30 minutes at 50°C. 
Then buffer was poured off and membranes were washed with TBST for several times. 
Subsequently, membranes were blocked for 1 hour (at room temperature) or over night 
(at 4°C) with 5% BSA - TBST solution and incubated with antibodies as described above. 
 
Stripping-buffer: 
100 mM ß-Mercaptomethanol 
2 % SDS 
62,5 mM TRIS     
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List of used antibodies: 
 
1st antibody Label kDa source Dilution 
Laminin B1 Neomarker 210 Rat 1:1000 
ERK 1/2 Cell signal. 42; 44 Rabbit 1:1000 
pERK1/2 Cell signal. 42; 44 Rabbit 1:1000 
eIF4E Cell signal. 25 Rabbit 1:1000 
peIF4E Cell signal. 25 Rabbit 1:1000 
AKT Transd. Lab 59 Mouse 1:1000 
pAKT Cell signal. 59 Rabbit 1:1000 
4E-BP1 Cell signal. 15 – 20 Rabbit 1:1000 
p4E-BP1 Cell signal. 15 – 20 Rabbit 1:1000 
Actin Sigma 42 Rabbit 1:2500 
 
 
2nd antibody conjugate Label source Dilution 
Mouse IgG Peroxidase Vector Lab Horse 1:10000 
Rabbit IgG Peroxidase Vector Lab Goat 1:10000 
Rat IgG HRP Santa cruz Goat 1:5000 
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4.  Results 
 
Minimal sequence required for IRES-mediated translation of LamB1 
 
To gain insight into the changes of translation control during hepatocellular EMT, 
expression profiling of neoplastic epithelial MIM-Ras and metastatic fibroblastoid MIM-RT 
cells has been performed previously [161]. Evaluation of the data revealed a list of 
mRNAs suggested to be translationally up- or down-regulated. In particular, several 
components of the ECM including LamB1 were translationally upregulated upon 
hepatocellular EMT [110, 161]. Analysis of the 335 nt long and GC rich (68%) LamB1 5´-
UTR predicted a highly stable secondary structure with a minimal free energy of -154 
kcal/mol within the 5´-UTR [110]. Stable secondary structures within the 5´-UTR of 
mRNAs are generally assumed to hinder the ribosomal scanning process, thus impairing 
cap-dependent translation [119, 129, 163]. Investigations of the LamB1 5´-UTR 
translation efficiency by using reporter assays provided unexpected data. The 5´-UTR of 
human LamB1 could enhance the activity of a monocistronic reporter gene and 
additionally direct the translation of a bicistronic mRNA in murine hepatic carcinoma cells 
[110]. In summary, these data suggest that the leader region of LamB1 confers cap-
independent translation by internal ribosome entry site (IRES) [110].  
In order to localize the sequence responsible for the IRES activity, bicistronic reporter 
assays were performed. Multiple alignment of the LamB1 5´-UTR revealed that the 
sequence element which ranges from nucleotide position 150 to 335, is highly conserved 
between different species (Figure 14). Therefore, we generated bicistronic reporter 
constructs carrying different deletions of the 5-UTR. In particular, we examined three 
deletion fragments corresponding to region between nucleotide position 253 to 335, 200 
to 335 and 155 to 335 of the human LamB1 5´-UTR. The resulting deletions having a 
length of 82, 135 and 180 base pairs (bp), were cloned in the bicistronic vector between 
the ß-galactosidase and CAT reporter genes (Figure 15A). All deletions of the human 
LamB1-5´-UTR were generated by PCR and contained NheI and XhoI restriction sites for 
forced cloning. While the translation of the upstream ß-galactosidase reporter is cap-
dependent, the downstream CAT reporter is only translated in the presence of an IRES-
containing and upstream positioned 5´-UTR (p-ßgal-Lam-CAT, Figure 15B, 16A). 
Bicistronic reporter constructs carrying one of the three deletion fragments of the LamB1 
5´-UTR were generated (p-ßgal-155/ 200/ 253-CAT, Figure 15B and 16A). Furthermore, 
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a  bicistronic plasmid containing a 162 bp long segment of the XIAP 5´-UTR provided a 
positive control for IRES-mediated translation (p-ßgal-XIAP-CAT) [164]. An empty 
bicistronic vector was used as negative control (p-ßgal-CAT) (Figure 16A). Each of the 
six vectors were transfected into MIM-Ras hepatocytes (Figure 16B). Subsequently, the 
ratios of CAT to ß-galactosidase activities were evaluated. Figure 17A and 17B shows a 
30-fold upregulation of the p-ßgal-Lam-CAT plasmid compared to the negative empty 
control p-ßgal-CAT. Furthermore, the p-ßgal-Lam-CAT activity was 2-fold higher than the 
activity generated by the IRES-containing positive control p-ßgal-XIAP-CAT. Compared 
to p-ßgal-Lam-CAT activity, the analysis of the three constructs carrying LamB1 5´-UTR 
deletion fragments revealed decreased CAT activities, correlating with the length 
shortening of the analyzed deletions. The bicistronic construct containing the smallest 
deletion, p-ßgal-155-CAT, generated approximately 60% of the cap-independent CAT 
activity provided by the full length LamB1 5´-UTR. The p-ßgal-200 / 253-CAT constructs 
showed no more than 30% of the activity received by the p-ßgal-Lam-CAT plasmid. In 
conclusion, these data support the presence of an IRES motif in the leader region of 
LamB1 that allows cap-independent translation of LamB1 in murine carcinoma cells. 
From the data obtained by deletion analysis, we conclude that the sequence upstream of 
nucleotide 155 does not significantly contribute to cap-independent translation of the 
LamB1 5´-UTR. 
 
LamB1 is not translationally upregulated in the human (metastatic) colon cancer 
cell line SW620. 
 
It was previously reported that human LamB1 5´-UTR is translational upregulated in 
murine cancer cell lines as well as in a human cancer cell line [110, 112, 159]. Analysis 
of a bicistronic reporter construct containing the LamB1 5´-UTR revealed a 12-fold 
upregulation of reporter gene activity compared to a control plasmid in the human colon 
cancer cell line SW480 [110]. Notably, the increase of reporter gene activity was even 
higher in SW480 carcinoma cells than in murine MIM-Ras carcinoma cells. Accordingly, 
these data motivated us to establish a human EMT model in order to study the 
translational regulation of the LamB1 5´-UTR. Therefore we utilized the differentiated HT-
29 colon carcinoma cells, the epitheloid SW480 and the spindle-shaped (metastatic) 
human SW620 colon carcinoma cells. Monocistronic reporter assays were performed to 
examine the effect of the LamB1 5´-UTR on general translation in human cancer cells. 
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We established a construct which contains the 5´-UTR upstream of the Firefly luciferase 
reporter gene (pLam-F) (Figure 18) [110]. The Firefly luciferase reporter gene is driven 
by a CMV promoter that is flanked by short intron sequence (IVS). Another construct 
carrying the encephalomyocarditis virus (EMCV) 5´-UTR was used as a positive control 
for IRES-mediated translation (pEMCV-F) and an empty plasmid served as negative 
control (pF) (Figure 18) [110]. The constructs were transfected into the three described 
colon carcinoma cell lines (Figure 19A) and assayed for the relative Firefly luciferase 
activity. As shown in Figure 19B, an enhanced reporter activity mediated by the LamB1 
5´-UTR was detected in SW480 cells. In contrast, a strong decrease was measured in 
SW620 cells. As expected, the reporter activity of pLam-F was low in HT-29 cells but still 
higher compared to the negative control. Unfortunately, the relative Firefly luciferase 
activities of the positive control were in all transfected cell lines weaker than the empty 
vector activies. To confirm the obtained results, Western blot analysis was performed 
(Figure 19C). In accordance with the monocistronic reporter assay, the LamB1 protein 
level was upregulated in SW480 cells but not in SW620 cells. Taken together, these data 
confirmed a strong translational upregulation of LamB1 in SW480 colon cancer cells 
which exhibit increased malignancy. However, SW620 cells that have undergone EMT 
did only show a moderate increase in translation. 
  
Interference with IRES-mediated translation by the LamB1 3´-UTR 
 
Recent data revealed that the 3´-UTR of the mRNA communicates with the 5´-cap-
complex via interaction of poly(A)-binding protein (PABP) with the N-terminal part of 
eIF4G in order to modulate cap-dependent translation. The importance of the 3´-UTR 
within the IRES-mediated translation still remains to be investigated [144]. To elucidate a 
possible role of the LamB1 3´-UTR on translation of LamB1, we performed a 
monocistronic Firefly luciferase assay. Therefore, vectors containing either the full length 
LamB1 5´-UTR (pLamF) or no insert (pF) upstream of the open reading frame (ORF) of 
the Firefly luciferase reporter gene were generated (Figure 20) [110]. Furthermore, the 
LamB1 3´-UTR was inserted into pLam-F and pF vectors, generating the pLam-F-Lam 
and pF-Lam constructs (Figure 20). Western blot analsis of LamB1 expression in 
parental MIM-1-4 hepatocytes, malignant MIM-Ras and metastatic MIM-RT cells showed 
an upregulation of LamB1 protein with the increase of malignancy (Figure 21A). 
Therefore, the four established monocistronic reporter constructs were then transiently 
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co-transfected with ß-galactosidase plasmid into neoplastic MIM-Ras and metastatic 
MIM-RT hepatocytes (Figure 21B) and relative reporter gene activities were determined 
(Figure 22A, B). As expected, relative Firefly luciferase activities of the constructs 
containing the LamB1 5´-UTR showed enhanced values compared to the empty vector 
construct in MIM-Ras and MIM-RT cells (Figure 22A). Notably, the plasmid that 
additionally carried the LamB1 3´-UTR (pLam-F-Lam) could not maintain the reporter 
gene activity provided by the pLam-F construct (Figure 22A). The evalution of the relative 
Firefly luciferase activites normalized to the empty vector activities revealed that the 
observed decrease is stronger in MIM-RT cells than in MIM-Ras cells (Figure 22B). 
Interestingly, in the absence of the LamB1 5´-UTR (pF-Lam), the LamB1 3´-UTR was 
able to promote the translation of the reporter gene. The received reporter activities 
normalized to the empty vector activity showed higher translation than the results 
obtained from pLam-F plasmid (Figure 22B). Additionally, the impact of the LamB1 3´-
UTR on the Firefly luciferase activity was stronger in MIM-RT cells than in MIM-Ras cells 
(Figure 22B). From these data, we concluded that the regulatory role of LamB1 3´-UTR 
might depend on the sequence located upstream of the reporter gene. In the case of 
LamB1 5´-UTR, the data suggest that the LamB1 3´-UTR provides an inhibitory function 
on translation in hepatic carcinoma cells. 
 
Interference of the ILEI 3´-UTR with translation  
 
In order to detect novel EMT regulators, expression profiling was recently performed by 
employing total versus polysome-bound mRNAs of EpRas and Ep-XT breast carcinoma 
cells [82]. Within a cluster of genes specific for EMT and metastasis, the protein termed 
ILEI was revealed to be translational upregulated [82, 112]. ILEI belongs to a group of 
secreted proteins with largely unknown function (FAM3A-D) [82]. Experiments have 
recently shown that stable overexpression of ILEI causes EMT, tumor growth and 
metastasis in the mammary carcinoma EpH4/EpRas model (Figure 23A) [82]. 
Within our experiments, we focused on the question whether the translational 
upregulation of ILEI upon EMT is influenced by the 3´-UTR. Therefore, we compared the 
translation efficiency of a reporter gene in presence or absence of the ILEI 3´-UTR in a 
murine mammary EpH4/EpRas/Ep-XT tumor model which reflects EMT (Figure 23A). In 
order to rule out an interference of the ILEI 3´-UTR with translation, we performed a 
monocistronic reporter assay. We generated a construct where ILEI 3´-UTR is 
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downstream arranged of a CMV-driven Firefly luciferase reporter gene (Figure 23B). 
Plasmids with (pF-ILEI) or without the ILEI 3´-UTR (pF) were transiently transfected into 
nontumorigenic epithelial EpH4 cells, tumorigenic epithelial EpRas cells and metastatic, 
mesenchymal Ep-XT cells (Figure 23A). Subsequently, Firefly luciferase assays were 
performed out and the obtained reporter gene activities were normalized to the empty 
control vector activities. Interestingly, enhanced reporter activities in the presence of the 
ILEI 3´-UTR were obtained in all three cell lines. As shown in Figure 23C, the highest 
Firefly luciferase activity was measured in the mesenchymal Ep-XT cells. Additionally, 
we could observe a continuous increase of reporter gene activity corresponding to the 
progressive malignancy of the cell lines,  from EpH4 cells to EpRas cells towards Ep-XT 
cells. From these data we concluded that the ILEI 3´-UTR is able to promote translation 
depending on the malignant stage in mammary carcinoma cells. 
 
Signaling during hepatocellular EMT 
 
The LamB1 mRNA is considered to harbor an IRES motif that mediates cap-independent 
translation [110]. Importantly, IRES-dependent translation of LamB1 mRNA is of 
particular interest as LamB1 has been reported to have severe implications in tumor 
progression [110, 161]. Therefore, we aimed to highlight signaling events which are 
involved in the regulation of IRES-mediated translation of LamB1. In our experimental 
setting, we showed that LamB1 is translational upregulated during hepatocellular EMT, 
dependent on the collaboration of constitutive active Ras and TGF-ß [42]. It has been 
reported that TGF-ß signaling cooperates with Ras through activation of ERK/MAPK and 
PI3K/AKT pathways [94]. Noteworthy, these pathways are frequently activated in tumors 
and play an important role in translation control, for example by regulating the availability 
of ribosomal proteins and eukaryotic initiation factors [148]. In order to gain insight into 
the translational regulation during hepatocellular EMT model, we aimed to determine the 
activation of PI3K and MAPK pathways. Therefore, we performed Western blot analysis 
of MIM-1-4, MIM-Ras and MIM-RT cell lysates (Figure 24A). To investigate MAPK 
signaling, we determined the unphosphorylated and phosphorylated protein levels of 
ERK and eIF4E. With regard to the PI3K signaling, we examined the phosphorylation 
status of AKT and 4E-BP1 proteins. As shown in Figure 24B, Western blot analysis 
revealed that constitutive active Ras signaling provided an increase of phosphorylated 
ERK protein which correlates with the progression in malignancy from MIM-Ras to MIM-
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RT cells. As expected, unphosphorylated ERK protein levels kept constant in MIM-1-4 
and MIM-Ras cells as well as in fibroblastoid MIM-RT cells. The anti-(phospho)-ERK 
antibody detected two ERK proteins, one with 42 kDa (p42) and a second one with 44 
kDa (p44) molecular weight. Due to the fact that eIF4E-phosphorylation is mainly 
regulated by activated ERK, we expected a similar phosphorylation pattern of ERK and 
eIF4E proteins. As assumed, Western blot analysis revealed enhanced phosphorylation 
of eIF4E protein in MIM-RT cells as compared to MIM-14 and MIM-Ras cells. Levels of 
phosphorylated eIF4E in parental MIM-1-4 and neoplastic MIM-Ras cells were equal. 
Additionally, a slight increase of unphosphorylated eIF4E protein was detected in 
neoplastic MIM-Ras and MIM-RT cells compared to MIM-1-4. These data suggest that 
the availability of functional ERK and eIF4E is mainly provided by phosphorylation. 
Constitutive active Ras signaling might switch on translation via phosphorylation of ERK 
and eIF4E proteins, further leading to malignant transformation during EMT. Western blot 
analysis of phospho-AKT and AKT protein did not allow a proper interpretation but 
propose a slight increase for both proteins in MIM-RT cells. These data partially correlate 
with 4E-BP1 protein phosphorylation. Taken together, the eIF4E, AKT and 4E-BP1 
protein synthesis is upregulated in MIM-Ras cells, which show tumorigenic features as 
well as in MIM-RT cells, which have undergone EMT. In conclusion, Western blot 
analysis revealed that signal effectors of the MAPK and PI3K pathway, namely ERK, 
eIF4E and 4E-BP1 protein are activated by enhanced phosphorylation in our murine 
hepatocellular EMT model, suggesting that these signaling cascades might have a 
crucial role in cap- and cap-independent translation of LamB1.   
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5. Discussion 
 
As a subunit of the heterotrimeric Laminin, LamB1 belongs to a group of ECM proteins 
that are able to interact with surrounding cells [158]. These ECM-cell interactions affect 
multiple cellular processes such as cell adhesion, migration, proliferation and 
differentiation with the aim to maintain a physiological order within tissues [159]. All these 
processes are known to be crucial for the fate of malignant cells during tumor 
progression, suggesting an important role of Laminin in tumorigenesis. [160]. In addition, 
it is known that neoplastic epithelial cells frequently express aberrant Laminin receptors, 
directly correlating with enhanced invasiveness [110, 159]. Laminin signaling is mediated 
by laminin and integrin receptors which activate regulatory pathways involved in 
metastasis such as the MAPK and PI3K pathway [159-160]. Expression profiling of total 
versus polysome-bound mRNAs revealed LamB1 to be translational upregulated upon 
hepatocellular EMT [110, 161]. Actually, little is known about the translational regulation 
of LamB1 but some efforts have been performed to gain insight into the underlying 
molecular mechanisms. In this context, first evidence were recently presented for a cap-
independent translation initiation of LamB1 which allows cells to immediately respond to 
changes under (patho)-physiological conditions [110]. In particular, LamB1 5´-UTR was 
capable to direct IRES-driven translation of a bicistronic reporter assay. Moreover the 
LamB1 expression increased under conditions of impaired cap-dependent translation by 
expression of human rhinovirus 2A protease or heat shock of cells [110]. In order to 
respond to the common criticism of the bicistronic reporter assay that the downstream 
reporter activity can arise from the presence of cryptic promoter or splice sites rather 
than from a bona fide IRES, additional experiments confirmed that the activity was 
indeed mediated by IRES [110, 165].   
 
Finding the minimal sequence responsible for LamB1 IRES activity 
 
While the IRES-mediated translation mechanism is commonly accepted as an alternative 
mode of translation in situations of attenuated cap-dependent translation, little is known 
about the nature and the molecular details of cellular IRESs [126, 166]. Sequence 
analysis could not yet identify any similarities among known cellular IRESs [167]. Thus, 
IRESs form complex and stable secondary structures allowing them to interact with 
components important for translation initiation [119]. Recently, a strong correlation 
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between IRES activity and structural stability of several yeast and fruit fly IRESs was 
detected. The highest IRES activities were found in RNA segments harboring the 
weakest secondary structures [119]. However, in our study we focused on the human 
LamB1 IRES element with the aim to identify the region upstream of the initiation codon 
that retains full IRES activity and therefore is responsible for cap-independent translation 
initiation. Our experimental analysis of the full length LamB1 5´-UTR provided evidence 
for an initiation mechanism alternative to cap-dependent translation. In our bicistronic 
reporter assays, the LamB1 5´-UTR was able to direct translation in murine neoplastic 
hepatocytes. Notably, the bicistronic reporter construct containing the LamB1 5´-UTR 
showed a 30-fold upregulation compared to the control construct (Figure 17). In order to 
describe a possible in vivo structure of the 335 nt long and GC rich (68%) LamB1 5´-
UTR, Zuker algorithm has previously been performed and predicted a strong secondary 
structure with a minimal free energy of -154 kcal/mol [110]. Such a proposed stem-loop 
motif is likely to negatively interfere with the cap-dependent translation, as it has already 
been shown for secondary structures with a free energy up to -50 kcal/mol [163, 168-
169]. Interestingly, the predicted secondary structure lies within the nucleotide position 
180 to 335, the sequence which is highly conserved between different species (Figure 
14). In accordance with these data we assumed that the nucleotide sequence 180 to 335 
harbors the IRES activity. To determine the sequence responsible for translation 
initiation, we generated bicistronic reporter constructs containing different deletions of the 
LamB1 5´-UTR sequence. Unfortunately, none of the three tested fragments, 235 to 335; 
200 to 335 and 155 to 335 of the 5´-UTR retained full IRES activity. The sequence region 
155 to 335 reached 60% of the full length LamB1 5´-UTR activity, whereas the activity of 
the two shorter constructs significantly decreased (P<0,008), reaching only 30% of the 
full length LamB1 5´-UTR activity (Figure 17). Interestingly, the nucleotide segment 200 
to 335 and 253 to 335 showed similar activities, thus supposing that the sequence 
directly upstream of the initiation codon contains elements important for IRES activity. 
These data further suggest that the sequence from nucleotide 200 to 253 may be 
irrelevant for IRES activity. However, the assumption that the 30% activity from the 
sequence 200 to 335 could be the result of aberrant expressed transcripts rather than 
from IRES-driven translation, can be partly refused by the fact that the activity levels are 
comparable with the one from the XIAP positive control. The IRES motif of the human 
XIAP 5´-UTR is a well described example for a cellular IRES which directs strong cap-
independent translation and thus serves as optimal positive control to study the human 
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LamB1 5´-UTR [141]. Besides the unusual long 5´-UTR (>1,6 kb for human XIAP 
transcript) and the predicted complex secondary structure of the 5´-UTR, a 
polypyrimidine tract (PPT) located 34 nucleotides upstream of the initiation codon has 
been described. PPT deletion experiments revealed the need for the functional PPT in 
order to retain full XIAP activity. Therefore a specific sequence within the PPT may be 
criticial for XIAP activity, an observation firstly described in cellular IRESs [141]. 
Investigations on IRES of picornaviruses have shown that their translation activities are 
stimulated by noncanonical IRES trans-acting factors (ITAFs) such as polypyrimidine 
tract binding protein (PTB) or La autoantigen, presumably by stabilizing their active 
conformation [170]. These observations became relevant to us, as preliminary in silico 
analysis revealed as well PPTs (PPT-1, position -177 to -161; PPT-2, -204 to -194; PPT-
3, -297 to -289) within the LamB1 5´-UTR. Accordingly, the detected PPTs sequences 
may be indispensable for full LamB1 IRES function [141]. However, one must take into 
consideration that past efforts in searching for conserved structures or general 
mechanisms among cellular IRESs were unable to identify common features of cellular 
IRESs [167]. It remains to be determined whether the PPTs within the 5´-UTR may have 
relevance for LamB1 IRES activity. Furthermore, the functionality of the LamB1 IRES 
could be provided by a combined effect of short modules that promote internal initiation, 
as it is the case for c-myc [171]. The main future project involves the identification of 
ITAFs by using RNA affinity chromatography in order to examine the molecular 
mechanisms underlying the LamB1 IRES translation. To reveal other sequence elements 
involved into the cap-independent translation initiation process, future experiments 
should include the characterization of the yet not examined LamB1 5´-UTR sequence 
from nucleotide position 1 to 155. In this way, each PPT should be deleted to test 
whether the specific PPT sequence is required for internal translation by reduction of 
IRES activity. Further analysis will be required to analyze whether the PPT elements are 
sufficient to mediate IRES activity by simply testing just possible PPTs and by including 
experiments with mutated PPT versions. Our data together with results of future 
experiments are considered to determine the minimal sequence required for LamB1 
IRES-mediated translation. Previously identified and structural described cellular and 
viral IRESs may help us to interpret results of our LamB1 5´-UTR investigations. In this 
context we always have to keep aware that secondary structures of RNA generated and 
fold in vitro may differ from in vivo co-transcriptionally folded RNA [134].  
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The IRES-driven translation of LamB1 is of particular interest, as this ECM protein has 
severe implications in cancer progression [110]. Therefore the determination of the 
minimal IRES sequence for LamB1 biosynthesis may provide new insight into structural 
features important for the function of cellular IRESs in a neoplastic background.   
 
Human EMT model? 
 
EMT provides tumorigenic cells with mesenchymal features, thus enabling cancer cells 
to locally invade and metastasize throughout the human body [6, 46, 58, 63, 167]. In 
order to develop therapeutic strategies which help to hinder metastasis, various in vitro 
and in vivo EMT models have been established to study the molecular and cellular 
mechanisms and their regulatory components that drive this phenotypic conversion. In 
this regard, the ECM protein LamB1 was revealed to be involved within the EMT process 
[110]. LamB1 is translationally upregulated during hepatocellular EMT, what might be at 
least partially provided by an IRES motif in the leader region of LamB1 [110, 161]. The 
results from the present study support this observation as discussed. Beside the 
examination of the LamB1 gene expression in murine hepatic cell lines (Figure 17 and 
21), we aimed to employ a human in vitro EMT model corresponding to our murine 
model (MIM-1-4, MIM-Ras and MIM-RT cell lines) to investigate LamB1 translation. 
Therefore, we performed Western blot analysis of three colon cancer cell lines isolated 
from primary adenocarcinomas (HT-29 and SW480) and from a lymph node metastasis 
(SW620) derived from the same patient as the previously isolated SW480 cell line. Our 
analysis results demonstrate that only the primary tumor cell line SW480 expresses a 
prominent LamB1 level. Unfortunately, the assumed increase of LamB1 expression, as 
observed in the murine metastatic MIM-RT cell line, could not be detected in human 
metastatic SW620 cells (Figure 19 and 21). Consequently, these colon cancer cell lines 
are not suitable to study LamB1 translation during human EMT. However, there are 
possible interpretations to explain the differences of LamB1 expression in the examined 
human and murine cell lines. Firstly, the cells originate from primary tumors and from 
lymph node metastasis and therefore are adapted to different microenviroments. 
Accordingly, the cancer cells might increase or decrease specific protein levels such as 
those from LamB1, in order to adapt themselves to their actual environment. Secondly, 
the previous study concerning the translational regulation of LamB1 was perfomed in a 
murine EMT model, established by cancer cell lines that were in part genetically 
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manipulated in vitro. Therefore, one may assume that the features of the examined 
murine and human cancer cell lines, including LamB1 expression, basically differ.  
 
The regulatory impact of LamB1 and ILEI 3´-UTRs on translation 
 
Translational regulation is mainly directed by the interaction of RNA-binding proteins with 
the 5´- and/or 3´-UTR of the mRNA [126, 154]. Besides the various features of the 5´-
UTR that allow the regulation of the translation initiation process, the 3´-UTR has also 
other regulatory capacities such as regulation of mRNA stability [155-156, 172-173]. The 
complete regulatory potential of the mRNA UTRs is still unclear but so far investigations 
have already revealed some mechanisms for translational control, presenting another 
complex and well-organized level of gene expression regulation [113].  
An effective mechanism to modulate cap-dependent translation is mediated by the 
communication of the 3´-UTR with the cap-complex via the interaction of poly(A)-binding 
protein (PABP) with the N-terminal part of eIF4G protein [113]. Little is known about the 
involvement of the 3´-UTR on IRES-mediated translation [144]. Within our study, we 
aimed to analyze the impact of the LamB1 3´-UTR and its associated regulatory 
components on the IRES-dependent translation control. So far, we tested whether the 
LamB1 3´-UTR effects general translation efficiency in a monocistronic Luciferase assay 
in the presence or absence of the LamB1 IRES-containing 5´-UTR. Therefore, we 
compared the impact of LamB1 3´-UTR on translational activity in neoplastic MIM-Ras 
and metastatic MIM-RT cell lines (Figure 22). Our  results indicate an inhibitory effect of 
the LamB1 3´-UTR on translation in the presence of the IRES-containing LamB1 5´-UTR. 
In particular, the inhibition of translation mediated by the LamB1 3´-UTR was stronger in 
MIM-RT cells than in MIM-Ras cells. In contrast, in the absence of the LamB1 5´-UTR, 
LamB1 3´-UTR is able to increase translation. Enhanced translation activity was 
measured in both cell lines but again the effect was slightly stronger in MIM-RT cells. 
Notably, the employed monocistronic experimental setting allows no differentiation 
between cap-dependent or cap-independent translation. To complete our analysis, we 
additionally tested the influence of the LamB1 5´-UTR on translation in the absence of 
the LamB1 3´-UTR. Interestingly, LamB1 5´-UTR enhances translation efficiency in the 
LamB1 3´-UTR absence (Figure 22). In accordance with our actual knowledge about the 
3´-UTR influence on translational control, the obtained data do not allow us a clear 
conclusion. Our data neither suggest a general enhancing nor a general inhibitory effect 
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on cap-dependent translation. Results of several investigations have led to the concept 
of a functional interaction between the “head” and the “tail” of mRNA transcripts. The 
existence of a closed-loop or circular structure between the poly(A) tail and the 5´cap, 
mediated by PABP, has been described [113]. This transcript circularization is thought to 
promote translation initiation because of its ability to stimulate mRNA binding to the 
preinitiation complex (PIC) as well as to facilitate reinitiation by the post-termination 
ribosomes [113, 150]. Besides the important function of the poly(A) tail for cap-
dependent translation initiation, an indispensable role of the poly(A) tail for the IRES-
mediated translation is also proposed [113, 154]. For example, IRES-driven translation of 
c-myc and BiP mRNA was enhanced by the poly(A) tail in the absence of intact eIF4G 
and PABP [144]. Therefore, it is evident that the cap-independent translation is 
influenced by the poly(A) tail, whereas the impact of the remaining 3´-UTR sequence is 
still unclear. With respect to our data, we can detect a regulatory effect of LamB1 3´-UTR 
on both cap-dependent and cap-independent translation. However, further experiments 
will be needed to rule out underlying mechanisms. Together, our data suggest that the 
impact of the LamB1 3´-UTR to enhance or to inhibit translation might depend on the 
sequence or secondary structure present upstream of the initiation codon. However, 
there is no doubt that the 3´-UTR with its multiple binding sites for several regulatory 
factors possesses an eminent regulatory potential to alter gene expression [113]. Various 
factors such as microRNAs (miRNA) are able to target specific sites within the 3´-UTR, 
thus influencing different aspects of the mRNA such as mRNA metabolism, 
conformation, stability, localization or translational efficiency [113, 115, 174]. Therefore, 
sequence and structural analysis of the LamB1 3´-UTR has to be performed to reveal 
important regulatory elements which may help us to interpret our data. Furthermore, one 
must take into consideration that the 135 bp long LamB1 3´-UTR can be considered as a 
rather short 3´-UTR since quantitative analysis of UTRs suggest a mean 3´-UTR length 
of human transcripts > 500 bp [175-176]. In addition, it is hypothesized that the 3´-UTR 
length increases with evolution and with the complexity of organisms [113]. Therefore, 
one should address the question of what is the general consequence of shorter 3´-UTR 
as in the case of LamB1. In this context, it was recently reported that mRNAs with 
shorter 3´-UTRs, generated by alternative cleavage and polyadenylation (APA), exhibit 
increased stability and produce more protein, partly due to the loss of miRNA-mediated 
repression. Importantly, the incidence for APA is high in cancer cells, supposing a 
consequent loss of 3´-UTR repressive elements leading to oncogene activation [177].  
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Within our examinations concerning the regulatory role of 3´-UTRs on translation 
efficiency, we aimed to analyze the regulatory capacity of the 3´-UTR of ILEI on 
translation. This cytokine-like protein was recently shown to be both necessary and 
sufficient for EMT, tumorigenesis, and metastasis of normal epithelial cells [82]. In our 
experimental setting, we wanted to rule out an interference of the ILEI 3´-UTR with 
translation by using a monocistronic reporter assay. The presence of the ILEI 3´-UTR 
was able to enhance the translational efficiency of a reporter gene in murine breast 
cancer cell lines (Figure 23). Additionally, we show that the positive influence of the ILEI 
3´-UTR on translation progressively increases with the malignancy of cell lines. 
Therefore, the ILEI 3´-UTR is able to stabilize and enhance translational efficiency, an 
observation that goes together with the assumption that ILEI is upregulated exclusively at 
the translational level [82]. From previously performed in silico analysis, we found that 
the 1620 bp long ILEI 3´-UTR contains three polyadenylation sites, four miRNA binding 
site and several other regulatory elements. In this context, we suggest further 
investigations in order to highlight the existence of ILEI 3´-UTR isoforms and in particular 
to detect a possibly interference of one ILEI 3´-UTR isoform with a cellular state of 
malignancy.  
In conclusion, it remains unclear how those 3´-UTRs enhance or inhibit translation. So 
far, only few trans-acting proteins have been identified. Together with the low degree of 
conservation between 3´-UTR sequences, this knowledge makes functional predictions 
very difficult [174]. However, investigation of the extremely diverse translational control 
mechanisms hold promise for the future development of highly specific RNA-based 
therapies that may enable to target the expression of individual genes.    
 
MAPK and PI3K signaling during hepatocellular EMT 
 
We demonstrate the cap-independent translation of LamB1 during hepatocellular EMT, a 
process featuring several hallmarks of liver carcinoma progression [38]. The employed 
murine EMT model is represented by MIM hepatocytes that undergo EMT, caused by the 
synergy between oncogenic Ras and TGF-ß1 signaling [42, 178]. TGF-ß signaling 
cooperates with Ras through the activation of ERK/MAPK and PI3K/AKT signaling 
pathways [94]. Ras and PI3K/AKT are frequently activated in tumors and are known to 
play a crucial role in translation control and malignant transformation [148]. In this 
context, the PI3K/AKT/mTOR pathway regulates protein translation by activating the 
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ribosomal protein S6 and various translation initiation factors important for the 
recruitment of the ribosome to the mRNA [149, 179]. To gain insight into translational 
regulation of hepatocellular EMT, we focused our investigation on the activation of MAPK 
and PI3K pathways. In general, the PI3K/AKT/mTOR and Ras/MAPK cascades signal 
towards the components of the translation machinery, thus regulating translation initiation 
process. mTOR, a downstream kinase of PI3K, directly phosphorylates 4E-BPs and S6 
kinases (S6Ks), which are components of the translation machinery, and indirectly 
activates the eukaryotic initiation factor (eIF) 4B and 4G [123, 180]. On the other hand, 
the Ras/MAPK pathway drives the phosphorylation of eIF4E and eIF4B. An important 
regulatory step within the cap-dependent translation initiation is the mRNA 5´cap 
recognition process by eIF4F complex [115, 121]. A number of different translation 
initiation factors, including the 5´cap-binding protein eIF4E, are essential in order to 
establish the eIF4F complex. The eIF4E antagonists, the unphosphorylated translation 
repressor protein 4E-BPs, compete with eIF4G for a common eIF4E-binding site. In the 
case of phosphorylation, the interaction of 4E-BPs with eIF4E is disrupted, thus leading 
to the recruitment of eIF4G to the 5´-cap by eIF4E and further activate cap-dependent 
translation [115]. Additionally, mitogenic and/or stress stimuli induce phosphorylation of 
eIF4E via MAPK/Erk, while the role of eIF4E phosphorylation concerning translation 
initiation remains controversial.  
In our Western blot analysis, the expression of LamB1 was enhanced in Ras-
transformed hepatocytes and again increased upon TGF-ß treatment (Figure 24). The 
translational upregulation of LamB1 might be provided by Ras-induced enhancement of 
cap-dependent translation. In this context, it has recently been shown that the 
upregulation of LamB1 correlates with enhanced IRES activity in a bicistronic reporter 
assay [110]. The authors point out that the IRES-driven translation appears to be 
relevant in situation of cellular stress which is provided by TGF-ß signaling upon the 
induction of EMT [94]. It is hypothesized that MAPK/ERK signaling generates resistance 
against TGF-ß mediated effects such as cell cycle arrest and apoptosis during the early 
phase of hepatocellular EMT, whereas PI3K/AKT signaling is activated by TGF-ß 
autocrine production and designate a maintenance phase [62, 94]. However, our 
Western blot analysis reveal elevated levels of phosphorylated ERK and phosphorylated 
eIF4E protein in Ras-transformed hepatocytes and further increases during TGF-ß 
mediated EMT, thus indicating an activation of the MAPK pathway. The analysis of the 
activation of the PI3K pathway are difficult to interpret but we suppose a slight increase 
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of phosphorylated AKT protein upon TGF-ß induced EMT. In contrast elevated 
(phospho)-4E-BP1 protein levels are considerably apparent in cells with constitutive 
active Ras signaling. Therefore we conclude that translational repressor protein 4E-BP1 
is partly deactivated upon hepatocellular EMT by AKT/PI3K mediated phosphorylation, 
thus leading to the release of the 5´-cap binding protein eIF4E. Finally, ERK/MAPK 
signaling mediates phosphorylation of liberated eIF4E protein, which in turn enables cap-
dependent translation initiation. However, further experiments have to confirm these 
data. In addition, we aim to highlight the activation status of other regulators involved in 
the regulation of cap-dependent and IRES-mediated translation. The knowledge about 
the regulation of translation in (de)differentiated cells may help to better understand 
human diseases such as cancer.  
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 Figure 14
Figure 14. Alignment of human Laminin B1 5´-UTR with different species revealed a 
highly conserved region between nucleotide position 180 to 335. Arrow indicates 
assumed IRES  localization. 
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Figure 15. Cloning of the ß-gal/CAT bicistronic reporter constructs containing
LamB1 5´-UTR deletions. A, Preparation of fragments of the Laminin B1 5´-
UTR. Three deletion fragments with a length of  82, 135 and 180 base pairs
from the LamB1 5´-UTR were generated by PCR and subsequent enzymatic
digestion, generates NheI and XhoI restriction site for cloning. B, Construction 
of bicistronic reporter constructs. Three different deletion fragments of the
LamB1 5´-UTR were ligated into a linearized bicistronic reporter plasmid. To 
investigate translation of reporter constructs, the three 5´-UTR deletions were
inserted between the ß-galactosidase and CAT reporter gene. UTR, 
untranslated region, ßgal, ß-galactosidase reporter gene, CAT, 
chloramphenicol acetyltransferase.
A
Figure 15
B
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Figure 16
B
30 µm
MIM Ras
CMV IVS SV40polyACAT p-ßgal-CATßgal
CMV IVS SV40polyACAT p-ßgal-XIAP-CATßgal XIAP5´UTR
p-ßgal-Lam-CATCMV IVS SV40polyACATßgal LamB15´-UTR
p-ßgal-155 Lam-CATCMV IVS SV40polyACATßgal LamB1155
p-ßgal-200 Lam-CATCMV IVS SV40polyACATßgal LamB1200
p-ßgal-253 Lam-CATCMV IVS SV40polyACATßgal LamB1253
Figure 16. A, Schematic diagram of vectors employed
in this study. The bicistronic vectors contain a XIAP, the
full length or deletion fragments of the LamB1 5´-UTR in 
the linker region between ß-galactosidase and CAT 
reporter. B, Phase contrast image of murine malignant
MIM-Ras hepatocytes which were transfected with
bicistronic reporter constructs containing deletions of 
the human LamB1 5´-UTR. Insert shows cells at higher
magnification. CMV, cytomegalovirus promotor; IVS, 
intervening sequence; ßgal, ß-galactosidase reporter
gene; CAT, chloramphenicol acetlytransferase; polyA, 
polyadenylation site; SV40, Simian virus 40; LamB1, 
Laminin B1; XIAP, X-linked Inhibitor of Apoptosis
Protein.
A
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Figure 17. Bicistronic reporter assays to 
identify the minimal sequence
requirement of the LamB1 5´-UTR for
cap-independent translation. Bicistronic 
reporter assays to identify IRES 
sequence. A, Three independent CAT/ß-
gal assays of MIM-Ras hepatocytes
transfected with bicistronic plasmids. 
MIM-Ras cells either expressed p-ßgal-
CAT, p-ßgal-XIAP-CAT, p-ßgal-Lam-CAT, 
p-ßgal-155 Lam-CAT, p-ßgal-200 Lam-
CAT or p-ßgal-253 Lam-CAT. Cells were
lysed 48 h after transfection and CAT 
values were normalized to ß-
galactosidase. B, Mean values of three
independent transfections of MIM-Ras
cells with bicistronic plasmids. Mean
values of normalized CAT activities are
shown. Asteriks indicate significant
differences between full length LamB1 5´-
UTR and deletions of LamB1 5´-UTR (** 
P<0,008). CAT, chloramphenicol 
acetlytransferase; LamB1, Laminin B1; 
XIAP, X-linked Inhibitor of Apoptosis
Protein.
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Figure 18
CMV IVS SV40polyAFirefly pF
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Figure 18. Schematic diagram of monocistronic vectors used to analyze LamB1 
translation in human colon cancer cells. The monocistronic vectors contain an EMCV 
or LamB1 5´-UTR upstream of the Firefly luciferase reporter gene. CMV, 
cytomegalovirus promotor; EMCV, encephalomyocarditis virus; IVS, intervening
sequence; LamB1, Laminin B1; polyA, polyadenylation site; SV40, Simian virus 40.   
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Figure 19
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Figure 19. Analysis of LamB1 5´-UTR-dependent translation in human colon cancer
cells. A, Phase contrast microscopy of polarized HT-29, epitheloid SW480 and 
fibroblastoid SW620 human colon cancer cells. Inserts show cells at higher
magnification. B, Firefly luciferase assay of human colon cancer cells, transfected with
monocistronic pF, pEMCV-F or pLamF plasmids. Cells were lysed 48 h post-transfection
and the firefly activity was normalized to ß-galactosidase levels. C, Western Blot analysis
of LamB1 in colon cancer cell lines. Actin is shown as loading control. EMCV, 
encephalomyocarditis virus; LamB1, Laminin B1.
47
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Figure 20
Figure 20. Schematic diagram of vectors used to study the impact of the LamB1 3´-
UTR on LamB1 translation. Monocistronic vectors contain either the LamB1 5´-UTR 
upstream or the 3´-UTR downstream of the reporter gene. Additionally, a 
monocistronic vector containing both LamB1 5´- and 3´-UTR was employed. CMV, 
cytomegalovirus promotor; IVS, intervening sequence; LamB1, Laminin B1; polyA, 
polyadenylation site; SV40, Simian virus 40.
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Figure 21
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Figure 21. A, Western Blot analysis of 
LamB1 in parental MIM-1-4, neoplastic
MIM-Ras and fibroblastoid-MIM RT cells. 
Actin is shown as loading control. B, 
Phase contrast microscopy of polarized
tumorigenic MIM-Ras and unpolarized
metastatic MIM-RT treated with 1 ng/ml 
TGF-ß 1. Inserts show cells at higher
magnification. LamB1, Laminin B1.
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Figure 22
A
Figure 22. Monocistronic reporter assays to detect regulatory capacities of the 3´-
or 5´-UTR of LamB1. A, Results of two independent reporter assays are shown. 
Firefly luciferase activity of MIM-Ras and MIM-RT hepatocytes transfected with
either monocistronic pF, pLam-F, pF-Lam or pLam-F-Lam. Cells were lysed 48 h 
after transfection and Firefly luciferase activity was normalized to ß-galactosidase
levels. B, Diagram presents mean values of two independent performed
transfections normalized to pF values (A). LamB1, Laminin B1.
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Figure 23. A, Phase contrast microscopy of 
epithelial EpH4, polarized tumorigenic
EpRas and the fibroblastoid Ep-XT cells. 
Inserts show cells at higher magnification. 
B, Schematic diagram of employed
transfection vectors. The monocistronic
reporter construct in the absence or
presence of ILEI 3´-UTR downstream of the
Firefly reporter gene. C, Firefly luciferase
assay of murine EpH4, EpRas and Ep-XT
mammary cells transfected either with
monocistronic pF or pF-ILEI. Cells were
lysed 48 h post-tranfection and the Firefly
luciferase activity was normalized to ß-
galactosidase. Diagram presents mean
values of three independent performed
transfections normalized to pF values. CMV, 
cytomegalovirus promotor; IVS, intervening 
sequence; ILEI, Interleukin-like EMT 
inducer; polyA, polyadenylation site; SV40, 
Simian virus 40.
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Figure 24. A, Phase contrast microscopy
of parental MIM-1-4, neoplastic MIM-Ras
and fibroblastoid MIM-RT cells. Inserts
show cells at higher magnification. B, 
Western Blot analysis of LamB1 and 
regulators of the MAPK/PI3K signalling
pathways in murine hepatic cell lines. Actin
is shown as loading control.
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7. Abbreviations 
 
APC adenomatous polyposis coli 
Bcl B-cell lymphoma 
ß–cat ß-catenin 
CAM cellular adhesion molecule 
CBP Creb-binding protein 
ECM extracellular matrix 
EGF epidermal growth factor 
eIF eukaryotic initiation factor 
ELISA enzyme linked immunosorbent assay 
EMCV encephalomyocarditis virus 
EMT epithelial to mesenchymal transition 
ERK extracellular-signal-regulated kinase 
FAK focal adhesion kinase 
FGF fibroblast growth factor 
Fas-L Fas-ligand 
GF growth factor 
GFP green fluorescent protein 
GS growth signal 
GSK-3ß glycogen synthase kinase ß 
Ha-Ras Harvey rat sarcoma viral oncogene 
HCC hepatocellular carcinoma 
HCV hepatitis C virus 
HGF hepatocyte growth factor 
IGF insulin-like growth factor 
IGR ionotropic glutamate receptor 
IL interleukin 
ILEI interleukin-like EMT inducer 
IRES internal ribosome entry site 
ITAF IRES-trans acting factor 
JAK Janus kinase 
Jnk c-Jun amino-terminal kinase 
kDa kilodalton 
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LamB1 Laminin B1 
MAPK mitogen activated protein kinase 
MET mesenchymal to epithelial transition 
MMP matrix metallo protease 
mTOR mammalian Target of Rapamycin 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NIC notch intracellular domain 
ORF open reading frame 
PDGF platelet derived growth factor 
PABP poly(A)-binding protein   
PI3K phosphatidylinositol-3’-kinase 
PKB protein kinase B  
PKR protein kinase RNA 
PPT polypurine tract 
pRb retinoblastoma protein 
PTB polypyrimidine tract binding 
PTEN Phosphatase and Tensin homolog 
Raf rapidly growing fibrosarcoma 
Ras rat sarcoma viral oncogene 
RhoA Ras homolog gene family member A 
RISC RNA-induced silencing complex 
RNP ribonucleoprotein 
R-Smad receptor-regulated Smad 
RTK receptor tyrosine kinases 
SARA Smad anchor for receptor activation 
SCID severe combined immuno deficient mice 
SMURF Smad-specific E3 ubiquitin protein ligase 
Src avian sarcoma (schmidt-ruppin A-2) viral oncogene  
STAT signal transducer and activator of transcription 
TACE trans-arterial percutaneous chemo-embolisation 
TF transcription factor 
TGF-ß transforming growth factor 
TGIF TGF-ß induced factor 
TNFα Tumor necrosis factor α 
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TßR transforming growth factor receptor 
uPA urokinase-Typ Plasminogen Aktivator 
UTR untranslated region 
VEGF vascular endothelial growth factor 
VEGF-R vascular endothelial growth factor receptor 
Wnt Wingless-type MMTV (murine mammary tumor virus) integration site 
XIAP X-linked inducer of apoptosis 
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